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ABSTRACT 
Background: Recent innovations in molecular diagnosis such as nucleic acid sequence-
based amplification (NASBA) and polymerase chain reaction (PCR) products have 
opened perspectives for robust and rapid point-of-care molecular tests as a real alternative 
for parasitological and serological diagnosis in leishmaniasis together with the potential 
of differentiating species and subspecies in one test. The objectives of this study are  to 
determine the leishmania species of  isolates from eastern Sudan, to evaluate the 
repeatability and reproducibility of NASBA and PCR followed with 
oligochromatography (OC)  for the detection of Leishmania  in a ring trial multicenter 
study and to evaluate the performance of both  tests  in phase II study  using  clinical 
leishmaniasis samples from Sudan and Kenya as well as  to develop ribosomal DNA 
internal transcribed spacer 1(rDNA-ITS1) species-specific PCRs that discriminate 
between old world leishmania species. Methods: The rDNA-ITS1 and  Leishmania 
Cysteine proteinase B species-specific PCRs were  used for typing of 22 leishmania 
isolates .In addition 34 samples were tested blindly by both  NASBA-OC and PCR-OC in 
the ring trial and   a laboratory based  evaluation of both tests was also performed using 
Sudanese (247) and Kenyan(182) leishmaniasis samples.Furthermore,four species-
specific (PCRs) amplifying ITS1 were developed to discriminate L. aethiopica, L. 
tropica, L. major, and the L. donovani complex;  these PCRs use the same cycling 
conditions, and include an internal amplification control. Principal Findings: All the 
leishmania isolates belong to donovani sub-species within the donovani complex. 
NASBA-OC and PCR-OC tests showed high repeatability and reproducibility in the ring 
trial study.  In phase II study using Sudanese samples, the PCR-OC (OligoC-TesT) as 
well as the NASBA-OC showed a sensitivity of 96.8% (95% CI: 83.8%–99.4%) on 
lymph node aspirates and of 96.2% (95% CI: 89.4%–98.7%) on blood from the 
confirmed VL cases. The sensitivity on bone marrow was 96.9% (95% CI: 89.3%–
99.1%) and 95.3% (95% CI: 87.1%–98.4%) for the OligoC-TesT and NASBA-OC, 
respectively. All confirmed CL and PKDL cases were positive with both tests. The 
specificity on the healthy endemic controls was 90% (95% CI: 78.6%–95.7%) for the 
OligoC-TesT and 100% (95% CI: 92.9%–100.0%) for the NASBA-OC test. On the 
suspected VL cases, we observed a positive OligoC-TesT and NASBA-OC result in 
37.1% (95% CI: 23.2%–53.7%) and 34.3% (95% CI: 20.8%–50.9%) on lymph, in 72.7% 
(95% CI: 55.8%–84.9%) and 63.6% (95% CI: 46.6%–77.8%) on bone marrow and in 
76.9% (95% CI: 49.7%–91.8%) and 69.2% (95% CI: 42.4%–87.3%) on blood. Seven out 
of 8 CL suspected cases were positive with both tests. The specificity on the healthy 
endemic controls was 90% (95% CI: 78.6%–95.7%) for the OligoC-TesT and 100% 
(95% CI: 92.9%–100.0%) for the NASBA-OC test. On Kenyan samples, the Leishmania 
OligoC-TesT showed a sensitivity of 96.4% (95% [CI]: 90–98.8%) and a specificity of 
88.8% (95% CI: 81–93.6%), while the sensitivity and specificity of the NASBA-OC were 
79.8% (95% CI: 67–87%) and 100% (95% CI: 96.3–100%), respectively. The species 
specific PCRs can amplify up to 0.1 pg of Leishmania DNA, while being 100% specific 
for species identification on an extensive panel of geographically representative strains 
 XI
and isolates; they could also be used for leishmania species identification in clinical 
specimens. Conclusions: The entire 22 leishmania isolates lie within the donovani 
complex in the rDNA-ITS1 phylogeny with almost identical sequence, and they are all of 
L.donovani sub-species. NASBA-OC and PCR-OC showed high sensitivity on lymph, 
blood and tissue scrapings for diagnosis of VL, CL and PKDL in Sudan and Kenya, but 
the specificity for clinical VL was significantly higher with NASBA-OC. The ITS1 
species specific PCRs presents the first step towards a standardized typing assay for Old 
World Leishmania species. Recommendations: Further characterization with ITS1 of 
leishmania isolates from different parts of the Sudan is needed in order to have   a 
comprehensive picture of the distribution of the species causing leishmaniasis in Sudan, 
The Leishmania OligoC-TesT and NASBA-OC can be used as powerful diagnostic tests 
in disease surveillance programmes and in monitoring intervention studies. Phase 11 
evaluation of the rDNA species specific PCR using an extended set of clinical samples 
from leishmaniasis patients with different clinical presentation is recommended. 
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 1. Introduction & Literature review 
1.1.Leishmaniasis Overview: 
            The trypanosomatid parasite of the genus leishmania is the etiological agent of a 
variety of disease manifestations, collectively known as Leishmaniasis. Leishmaniasis is 
prevalent in 66 nations throughout the tropical and sub-tropical regions of Africa, Asia, 
the Mediterranean and Southern Europe (old world) and in 22 countries in South and 
Central America (new world) [1].  Despite enormous efforts, it has proved difficult to 
predict the exact scale of the impact of leishmaniasis on public health, since many cases 
go unreported or misdiagnosed. It is estimated that approximately 12 million people are 
currently infected and a further 367 million are at risk of acquiring leishmaniasis in 88 
countries, 72 of which are developing countries and 13 of them are among the least 
developed in the world [2] 
The leishmaniasis can be classified into 4 main clinical forms: 
1. Visceral leishmaniasis (VL) - the most serious form is fatal if left untreated (e.g. Kala 
azar due to L. donovani s.l.). More than 90% of visceral leishmaniasis cases occur in 
Bangladesh, Brazil, India and Sudan.  
2. Cutaneous leishmaniasis (CL) - the most common form, causes 1-200 simple skin 
lesions which self-heal within a few months but which leave unsightly scars. (E.g. 
Baghdad ulcer, Delhi boil or Bouton d’Orient, due to infection with L. major in Africa 
and Asia). More than 90% of cutaneous leishmaniasis cases occur in Iran, Afghanistan, 
Syria, and Saudi Arabia, Brazil and Peru. Most cases of CL heal without treatment, 
leaving the person immune to further infection. In many parts of South-west Asia, 
infections were deliberately encouraged on the buttocks of babies in order to immunize 
them (avoiding disfiguring scars on the face or elsewhere).  
3. Mucocutaneous leishmaniasis (MCL), due to L. braziliensis infection in the New 
World, begins with skin ulcers which spread, causing dreadful and massive tissue 
destruction, especially of the nose and mouth. 
4. Diffuse cutaneous leishmaniasis (DCL) due to L.aethiopica in old world and 
L.mexicana in new world, produces disseminated and chronic skin lesions resembling 
those of leprotamous leprosy. It is difficult to treat [2, 3].  
The parasitic protozoa of the genus Leishmania is mainly transmitted to humans by sand 
flies. Over 20 species and subspecies infect humans. Humans are infected via the bite of 
sand flies (subfamily phlebotominae) - tiny sand-colored blood-feeding flies that breed 
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in forest areas, caves, or the burrows of small rodents. Wild and domesticated animals 
and humans themselves can act as a reservoir of infection. Rarely, leishmaniasis is 
spread from a pregnant woman to her baby. Leishmaniasis also can be spread by blood 
transfusions or contaminated needles [4]. Most forms of leishmaniasis are originally 
infections of small mammals (‘reservoir hosts’), which play a major role in the 
epidemiology of the disease. Old World forms of Leishmania are transmitted by sand 
flies of the genus Phlebotomus, while New World forms mainly by flies of the genus 
Lutzomyia. Sand flies become infected by ingesting blood from infected reservoir hosts 
or from infected people [5, 6]. 
The diagnosis of leishmaniasis is conventionally confirmed by demonstration of 
parasites although some forms of leishmaniasis are extremely difficult to diagnose by 
parasitology [7]. Parasitological diagnostic methods include: Microscopic examination, 
culture and inoculation of aspirates into animals. It is the method of choice and it 
depends on local resources. Other approaches include serodiagnosis which is based on 
detection of circulating antibody [8]. It is highly sensitive for diagnosing VL and useful 
for diagnosing MCL disease but less useful for diagnosing other forms of CL. Usually it 
is a support to a parasitological diagnosis but sometimes it is appropriate for use under 
field conditions. The techniques include: Aldehyde (formal gel), direct agglutination 
test (DAT), enzyme-linked immunosorbent assay (ELISA), Indirect fluorescent 
antibody test (IFAT) and recombinant antigens. Other laboratory investigations include 
the polymerase chain reaction (PCR)[9,10]: It is a sensitive and specific technique for 
detecting and identifying specific leishmania DNA sequences but it requires advanced 
laboratory facilities and technical expertise so it is not suitable for field conditions. 
Leishmania species identification is important and techniques to identify leishmania 
species include: parasite biology, isoenzyme analysis, monoclonal antibodies, PCR, 
DNA or RNA hybridization to specific probes and analysis of kinetoplast maxicircle 
genes (kDNA) [5, 11, 12].  
Control measures that involve human cases include early: detection which can be active 
or passive. Vector and reservoir host control measures are expensive, requiring good 
infrastructure and maintenance – often giving results which are short-lived. Vector 
control, based on spraying with residual insecticides, can be effective where 
transmission occurs in and around the home. Where transmission occurs away from 
home, individuals should use some form of protection, such as insect repellent or 
insecticide [13, 14]. The leishmaniases, as a complex of diseases, are as yet impossible 
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to control with a single approach or tool (a vaccine may prove a cost-effective 
exception). Control depends on early case detection and drug treatment where the 
reservoir is infected human. Recently, resistance to drugs has been reported, requiring 
the use of more toxic drugs, such as amphotericin B. Most available drugs are costly, 
require long treatment regimes and are becoming more and more ineffective, 
necessitating the discovery of new drugs [14, 15]. 
1.2 LEISHMANIASIS IN SUDAN: 
VL (kala-azar) has been among the most important health problems in Sudan, 
particularly in the main endemic area in the eastern and central regions since the early 
1900s [16, 17]. Several major epidemics have occurred; the most recent was in Western 
Upper Nile province in southern Sudan, detected in 1988-claiming over 100,000 lives 
[18]. The disease has spread to other areas that were previously not known to be 
endemic for VL. A major upsurge in the number of cases was noted in the endemic area 
of eastern Sudan. These events triggered renewed interest in the disease [19]. 
Phlebotomus orientalis was confirmed as the vector by various epidemiological and 
entomological studies in several parts of the country, typically associated with Acacia 
seyal and Balanites aegyptiaca vegetation [20, 21]. Twelve Leishmania isolates from 
VL patients in eastern Sudan were characterized using isoenzyme analysis, Southern 
blotting and polymerase chain reaction (PCR) ‘fingerprinting’. Isoenzyme analysis 
revealed the presence of 3 zymodemes: (MON-18, MON-30 and MON-82), 
corresponding to Leishmania donovani sensu stricto, L. infantum and L. archibaldi (still 
of uncertain taxonomic status), respectively. Southern blotting and PCR ‘fingerprinting’ 
revealed identical patterns for all 3 zymodemes, which were indistinguishable from 
those of L. donovani s.s. [22]. Transmission indicates a human reservoir and 
anthroponotic transmission [23]. PKDL was much more common than expected (56% 
of patients with VL developed PKDL), but other post-VL manifestations were also 
found affecting the eyes (uveitis, conjunctivitis, blepharitis), nasal and/or oral mucosa 
[19].  Leishmania major, zymodeme LON-1 is responsible for CL in Sudan [24]. The 
disease is endemic in many parts of the country; major epidemics occurred in northern 
Sudan, in Shendi- Atbara area in 1976 [25] and in Tuti island at the junction of the 
White and Blue Nile rivers in Khartoum state [26]. The vector is Phlebotomus papatasi 
and the animal reservoir is probably the Nile rat Arvicanthis niloticus [21, 27], the 
vectors being domestic and peridomestic in the villages [28]. Patients usually present 
with papules, nodules, or nodulo-ulcerative lesions, mainly on the exposed parts of the 
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skin [29]. In 20% of cases the parasite disseminates through the lymphatics, producing 
sporotrichoid-like lesions [30]. The diagnosis is confirmed by the demonstration of 
parasites in slit smears in 50-70% of cases and in histological sections in 70% [31, 32]. 
With primers specific for L. major, the polymerase chain reaction is positive in 86% of 
cases [33]. Since CL is a self-limiting disease, treatment is confined to patients with 
severe disease [29]. 
Sudanese MCL is a chronic infection of the upper respiratory tract and/or oral mucosa 
caused mainly by Leishmania donovani [34]. The disease occurs in areas of the country 
endemic for visceral leishmaniasis, particularly among Masalit and other closely related 
tribes in western Sudan [35]. The condition may present in most cases as a primary 
mucosal disease though it may develop during or after an attack of visceral 
leishmaniasis [36]. In contrast to South American MCL, mucosal leishmaniasis in 
Sudan is not preceded or accompanied by a cutaneous lesion. Parasites are scanty. 
Diagnosis is established by demonstration of parasites in smears or biopsies, by culture 
or animal inoculation, or with the aid of the polymerase chain reaction. Most patients 
give positive results in the direct agglutination test and leishmanin skin test. Patients 
respond well to treatment with pentavalent antimony compounds [37]. 
1.3. DIAGNOSIS OF LEISHMANIASIS: 
The broad clinical spectrum of the leishmaniasis makes the diagnosis of present and 
past cases difficult. However, differential diagnosis is important because diseases of 
other aetiologies with a clinical spectrum similar to that of the leishmaniasis (e.g., 
leprosy, skin cancers, and tuberculosis for CL and malaria and schistosomiasis for VL) 
are often present in areas of endemicity. Moreover, the severity of the clinical disease 
severity varies according to the infecting Leishmania species, and there is growing 
evidence that the therapeutic response is species and, perhaps, even strain specific. 
1.3.1. MICROSCOPY AND CULTURE:  
Parasitological diagnosis remains the gold standard in leishmaniasis diagnosis because 
of its high specificity. This is typically undertaken by microscopic examination of 
Giemsa-stained lesion biopsy smears (CL) or lymph node, bone marrow, and spleen 
aspirates (VL). Occasionally, histopathological examination of fixed lesion biopsies or 
culture of biopsy triturates and aspirates is also performed. Microscopy is probably still 
the standard diagnostic approach at tertiary, secondary, or even primary health levels in 
areas of endemicity, because more sophisticated techniques are currently expensive and 
rarely available. Importantly, the sensitivity of microscopy and culture tends to be low 
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and can be highly variable, depending on the number and dispersion of parasites in 
biopsy samples, the sampling procedure, and most of all the technical skills of the 
personnel [7]. 
1.3.2. SEROLOGICAL TECHNIQUES:    
Several serological approaches are commonly used in VL diagnosis. In particular, 
freeze-dried antigen-based direct agglutination tests and commercially available 
immunochromatographic dipstick tests have increasingly become reference tests in 
operational settings since they have high sensitivity and specificity, are easy to use, and 
require minimal technological expertise or laboratory setup [8]. Serological tests are 
rarely used in CL diagnosis because sensitivity can be variable and because the number 
of circulating antibodies against CL-causing parasites tends to be low (e.g., if previous 
chemotherapy has been administered). The specificity can also be variable, especially in 
areas where cross-reacting parasites (e.g., Trypanosoma cruzi) are prevalent. The 
Montenegro skin test (MST) is occasionally used in CL diagnosis (e.g., in 
epidemiological surveys and vaccine studies) because of its simple use and because of 
its high sensitivity and specificity [38]. The MST has major drawbacks which include 
that it requires culture facilities to produce the MST antigen, that different antigen 
preparations impact test sensitivity, and that the test does not distinguish between past 
and present infections. The MST is not used for VL diagnosis, since patients only 
develop strong Leishmania-specific cell-mediated immunity when cured [39]. 
1.3.2.1 THE DIRECT AGGLUTINATION TEST (DAT):  
The DAT is a semi-quantitative test that uses microtitre plates in which increasing 
dilutions of patient’s serum or blood are mixed with stained killed L. donovani 
promastigotes [40]. Agglutination is visible after 18 hours with the naked eye if specific 
antibodies are present. The storage of the antigen at 2–8°C once it has been dissolved 
and the prolonged incubation time are other drawbacks. Freeze-dried antigen is more 
robust than liquid antigen [41]. Through the way of improving DAT, DAT-Mod 
presented with adequate reproducibility between the three batches, resulting in variation 
coefficients from 0 to 5.8% [42].  A cut-off titer of higher serum dilutions generally 
yields higher specificities [43].  Using a cut-off titer of 1:100, [42] there were only four 
false-negative and three false positive results, which indicates a high sensitivity (93.4%) 
and specificity (96.9%). These rates are comparable [44] when the industrialized kit 
(DAT-FD) using the same cut-off titer (1:100) was used. 
1.3.3. MOLECULAR DIAGNOSIS:  
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    Although different molecular methods have successively been evaluated for 
leishmaniasis diagnosis (e.g., pulsed-field gel electrophoresis and multilocus enzyme 
electrophoresis), PCR-based assays currently constitute the main molecular diagnostic 
approach of researchers and health professionals. Several distinct PCR formats are 
available that may broadly be classified into “mid-tech,” “high-tech,” and “low-tech” 
approaches. Mid-tech approaches are probably the most widely used, and comprise 
conventional PCR assays, in which PCR amplicons are resolved by electrophoresis 
(eventually after cleavage with restriction enzymes, i.e., PCR and restriction fragment 
length polymorphism analysis [PCR-RFLP]) and visualized after ethidium bromide 
staining [45]. These assays are performed with several pieces of laboratory equipment 
(e.g., a thermocycler, a power supply, an electrophoresis tank, a UV transilluminator, 
and a camera) available in any standard molecular laboratory and are generally time-
consuming (which may considerably alter the cost of analysis, depending on the 
personnel costs). High-tech approaches are methods in which PCR products are 
analyzed during their amplification (so-called real-time PCR) after staining with SYBR-
green I dye or hybridization with fluorogenic probes (e.g., TaqMan or fluorescence 
resonance energy transfer [FRET]) [46]. In this case, assays are performed with a single 
all-in setup, and the detection of fluorescence is done within a closed tube, decreasing 
the risk of laboratory contamination by amplicons. Applications are rapid and of high 
throughput, but equipment are comparatively expensive and working costs remaining 
high. Low-tech approaches refer to simplified PCR methods for use in laboratory 
settings with minimal equipment [47]. Simplification can potentially be done at the two 
main steps of the PCR protocol: target amplification and detection of the PCR products. 
Loop-mediated isothermal amplification (LAMP) represents a promising avenue for 
both steps: it requires only a simple water bath for amplification, and detection can be 
done visually by using SYBR-green I dye, which turns green in the presence of 
amplified products and remains orange in its absence [48]. The method was claimed to 
be 100 times more sensitive than conventional PCR in the detection of Trypanosoma 
brucei [49]. Simplification of detection has been attempted by PCR-enzyme-linked 
immunosorbent assay (ELISA), a "reverse hybridization" method based on the capture 
of PCR amplicons by specific probes immobilized in ELISA microtiter wells and 
colorimetric visualization. High sensitivity was observed in blood samples from HIV-
negative VL patients [50]. However, in PCR-ELISA, detection is still dependent on 
sophisticated equipment (i.e., an ELISA plate reader).  
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1.3.3.1 PCR-OC 
More recent methods, such as oligochromatography-PCR (OC-PCR), represent a more 
promising alternative. This method requires a PCR cycler and a water bath, and PCR 
products are visualized in 5 minutes on a dipstick through hybridization with a gold-
conjugated probe; an additional advantage is that internal PCR controls can be placed 
onto the dipstick. Phase I evaluation of a first OC-PCR prototype for the diagnosis of 
sleeping sickness and leishmaniasis revealed 100% sensitivity and specificity [51, 52]. 
1.3.3.2 NASBA 
 Is the most sensitive technique that allows detection and quantification of micro-
organisms [53, 54]. It is based on the isothermal amplification of RNA and detection of 
up to 48 samples can be performed in approximately 90 minutes.  In NASBA-OC the 
amplification products are detected by a simple and rapid dipstick method based on 
oligochromatography. This assay showed high sensitivity and specificity for 
Leishmania detection during the phase I evaluations [55]. 
1.4. IDENTIFICATION OF THE SPECIES OF LEISHMANIA: 
Leishmania transmission cycle and epidemiology depend on the particular infecting 
(sub) species. Therefore, exact identification of the parasite species causing the disease 
is essential in order to design the correct control strategy and to make decisions 
regarding treatment strategies. Leishmania parasites (old world) have been divided into 
different species primarily on the basis of clinical, biological, geographical and 
epidemiological criteria [56]. During the past two decades, intrinsic characteristics, such 
as biochemical and molecular data, have been used for the classification of Leishmania 
isolates. At present, isoenzyme analysis by electrophoresis is widely used for the 
identification of Leishmania (sub) species and up to now it still represents the reference 
technique for Leishmania identification [57]. The parasites can be identified by their 
enzymes electrophoretic mobilities and be grouped in taxonomic units termed 
zymodemes. However, isoenzyme analysis has many drawbacks, it is time consuming 
and laborious, requires culturing and obtaining the profile of 10–20 different enzymes. 
Molecular methods, such as Southern hybridization and PCR-based methods have 
become available; those are less laborious and more powerful to study variability 
between Leishmania species [58].  
1.4.1 SOUTHERN BLOTTING USING DNA PROBES:  
One of the first molecular characterization methods in use was Southern blotting using 
DNA probes. This method is tedious as it requires cultivation of promastigotes, DNA 
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extraction, gel electrophoresis, Southern blotting and hybridization [59]. DNA probes 
for identifying Leishmania spp. generally target (kDNA); because the kDNA minicircle 
molecules are present at 10 000 copies and have a variable region that differs from 
minicircle classes in the same network [60]. kDNA minicircle sequence probes have 
been developed for L .major [61], dermatropic and viscerotropic strains of L. infantum 
[62] and L. aethiopica [63]. Recently, a new minicircle class exclusive to Leishmania 
(Viannia) guyanensis was identified [64]. This allowed the development of a specific 
probe, which hybridized strongly only to L. (V.) guyanensis kDNA after medium 
stringency washing. Probes derived from different sequences of the nuclear DNA have 
also been described. A cDNA probe containing multiple copies of a 60-bp repetitive 
degenerate sequence isolated from L. donovani specifically hybridized only with 
isolates of the L. donovani complex [59, 65, 66] described two probes which could be 
used for the differentiation of Leishmania species. One probe, pDK10, can be used to 
distinguish the Old World CL causing species from L. donovani complex and the other, 
pDK20, to differentiate between all Old World Leishmania species.  
1.4.2 PCR-BASED TECHNIQUES FOR IDENTIFICATION:  
Many PCR-based techniques have been developed for the identification of Leishmania 
species. Species specific primers: the specificity of any given PCR assay can be adapted 
to specific needs by targeting conserved or variable regions in parasite DNA. In this 
way it is possible to characterize Leishmania to the level of the genus complex, species 
or even the individual isolate. For example, PCR amplification of mini-exon gene 
repeating units showed size and sequence variation amongst many Leishmania species 
[67], especially in the non-transcribed spacer region, which is distinct in length and in 
sequence among different Leishmania species [68].  Random amplified polymorphic 
DNA (RAPD) uses a single primer of arbitrary sequence at a low annealing temperature 
to produce a PCR fingerprint-banding pattern after gel electrophoresis. This method 
does not depend upon previous knowledge or availability of the nucleotide sequence of 
the target nor does it require DNA hybridization [69]. However, the RAPD method has 
one major drawback: it can only be used on cultured parasites free of contaminating 
host DNA, which would mask the signal from the parasite DNA [70].  A correlation 
between RAPD pattern and isoenzyme analysis results was observed among different 
Leishmania isolates using six different arbitrary primers [71]. Four different, closely 
related Leishmania spp. from the Viannia group were used to evaluate 28 different 
RAPD primers. Thirteen of these primers yielded reproducible multiple banding 
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patterns of taxonomic value [70]. Amplification of genomic DNA with primers 
annealing to mini- and microsatellite DNA sequences yielded distinctive and 
reproducible sets of amplified DNA fragments for all Leishmania isolates tested. The 
number and size of amplification products were found to be characteristic for a given 
species.  By comparing PCR patterns of unidentified Leishmania isolates with those 
obtained from reference strains it is possible to identify these isolates at the species 
level [72]. 
1.4.3 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP):  
With RFLP a PCR amplicon is digested with a set of different restriction enzymes and 
resulting fragments are separated according to molecular size using gel electrophoresis. 
For example, by digesting the amplified small subunit ribosomal RNA PCR product 
with the restriction enzyme RsaI, it is possible to distinguish L. donovani from L. 
tropica and L. major [73].  The GP63 locus has been successfully used for the genetic 
characterization of a large number of natural isolates belonging to four species of the 
subgenus Viannia, namely L. (V.) braziliensis, L. (V.) peruviana, L. (V.) guyanensis and 
L. (V.) lainsoni [74, 75] has exploited the variability of the transcribed non-coding 
regions between the small and large subunit rRNA genes to examine relationships in the 
Viannia subgenus. In a method termed intergenic region typing (IRT), PCR 
amplification products were obtained for the rapidly evolving 1–1.2-kb internal 
transcribed spacers (ITS) between the small subunit (SSU) and large subunit (LSU) 
rRNAs, from 50 parasites isolated from different hosts and geographical areas. 
Amplified DNAs were cut with different restriction enzymes, and fragment patterns 
compared after acrylamide gel electrophoresis. High levels of intra- and interspecific 
variation were observed, and quantitative similarity comparisons were used to associate 
different lineages. A complex evolutionary tree was obtained. Some species formed 
tight clusters (L. equatorensis, L. panamensis, L. guyanensis, L. shawi), while L. 
braziliensis was highly polymorphic and L. naiffi showed intraspecific distances 
comparable to the largest obtained within all Viannia. L. colombiensis, L. equatorensis 
and L. lainsoni clearly represent distinct lineages. Good agreement was obtained with 
molecular trees based upon isoenzyme or mini-exon repeat sequence comparisons.  
Single strand conformation polymorphism (SSCP) analysis is based on the differences 
in the secondary structure of single-strand DNA molecules differing in a single 
nucleotide, which also is frequently reflected in an alteration of their electrophoretic 
mobility in nondenaturing gel electrophoresis. SSCP analysis was able to detect genetic 
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diversity at the level of a single nucleotide in a set of Sudanese L. donovani isolates            
[76] and in 29 L. tropica strains [77]. 
1.5. MOLECULAR TECHNIQUES AND TAXONOMY: 
Molecular techniques have provided new or improved views with regard to a number of 
taxonomic matters: So far no differences were found between L. infantum and L. 
chagasi, supporting the idea that L. chagasi and L. infantum are identical and that this 
species was introduced in the New World in the recent past, may be as part of the 
Spanish and Portuguese conquest of Latin America [78]. In another matter, the question 
whether Leishmania is a sexually or asexually reproducing organism, the current 
consensus seems to be that Leishmania has a basically clonal population structure with 
occasional bouts of genetic exchange or hybridization [79]. RFLP data suggest that the 
Old World Leishmaniasis comprise a monophyletic lineage, with species associated 
with cutaneous disease exhibiting the greatest level of divergence [80]. However, a 
number of taxonomic questions with regard to Leishmania remain open to debate. These 
are related to the Viannia subgenus and the taxonomic status of a number of New World 
complexes and have partly been addressed by [81]. 
1.6. NEW DEVELOPMENTS IN THE GENOME OF LEISHMANIA: 
1.6.1. GENOME SEQUENCING PROJECT: 
The Leishmania genome is a relatively small eukaryotic genome with an estimated size 
of 33.6 Mbp with a karyotype of 36 chromosomes, ranging in size from 0.3 to 2.5 Mbp 
[82]. In imitation of other genome sequencing projects, the Leishmania Genome 
Network (LGN) was established in Rio de Janeiro (Brazil) in 1994 and aimed at the 
genomic sequencing of the reference strain Leishmania major Friedlin [83]. The LGN is 
chaired by Professor J. M. Blackwell (Cambridge, UK) and 10 laboratories from seven 
countries are working for this project. The LGN is a programme supported by the 
UNDP/WORLD BANK/WHO – TDR and its website www.ebi.ac.uk/ 
parasites/leish.html is an important source for Leishmania sequence information, 
general information on parasites and their genomes and allows access to valuable 
bioinformatic tools via its links. The aim of the LGN was to obtain a detailed high 
resolution map of the reference strain L. major Friedlin (MHOM/IL/81/Friedlin). This 
has been achieved by the application of a number of complementary approaches: the 
determination of a pulsed field gel (PFG). Chromosomal ‘karyotype’, shuttle cosmid 
clone fingerprinting to generate overlapping contigs, sequencing and mapping of 
expressed sequence tags (ESTs) to PFG separated chromosomes and the generation of 
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DNA sequence from entire chromosomes. Sequencing of the whole genome is in 
progress. A first-generation cosmid contig map of L. major Friedlin genome has been 
constructed and sequencing of the genome is well under way with chromosome 1 
(Chr1) and Chr2 completed and Chr4 virtually complete [84]. Furthermore, active 
sequencing of Chr19, 23 and 35 is underway (LGN web site 2001). More than 600 
completely sequenced genes have been identified, an estimated 8% of the genome of 
approximately 8600 genes of Leishmania. Up to date, a large portion of the newly 
identified genes (> 60%) remains unclassified, with 40% of these being potentially 
Leishmania specific. Chr1, the smallest chromosome of L. major Friedlin, consists of 
three homologues which differ in size by approximately 29 kb. The complete sequence 
of Chr1 predicts that this chromosome has 79 protein coding sequences. The first 29 of 
these genes are encoded in tandem on one strand of DNA, and the remaining 50 genes 
are encoded on the other [85].  No RNA polymerase promoters, centromeric sequences 
or origins of DNA replication have been identified in the DNA sequence. Statistical 
analysis of Chr1 showed that the divergent junction region between the two 
polycistronic gene clusters may be a candidate for an origin of DNA replication [86]. 
In the coming years, the LGN will shift into the next phase: functional genomics and 
proteomics. This emerging area of research in the ‘post-genomic era’ deals with the 
global analysis of gene expression using a battery of techniques to resolve (by 2D 
PAGE), identify (by peptide sequencing, mass spectrometry, immunoblotting,…etc.), 
quantify and characterize proteins, as well as to store and interlink protein and DNA 
sequence and mapping information from the genome projects. This will aid 
identification of the molecular determinants of virulence in Leishmania and new 
strategies that can be exploited in the search for new therapies and vaccines. 
1.6.2 MICROARRAYS: 
The biological functions of only a fraction of the genes that are identified in genome 
projects are known. Traditional molecular biological methods work on one gene-one 
experiment basis and because of the limited throughput of such methods, the whole 
picture of gene function is difficult to obtain. In contrast, the recently developed 
microarray technology, in which DNA molecules representing many genes are placed in 
thousands of discrete spots on a microscope slide, allows scientists to look at many 
genes at once and to determine which ones are expressed in a particular cell type. Total 
mRNA from cells in two different conditions is extracted and labelled with two 
different fluorescent labels: for example, a green dye for cells at condition 1 (e.g. the 
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Leishmania promastigote stage) and a red dye for cells at condition 2 (amastigote 
stage). Both extracts are washed over the microarray. Labelled gene products from the 
extracts hybridize to their complementary sequences in the spots because of base 
pairing. The fluorescent dyes enable measuring the amount of sample. If the RNA from 
the promastigote is in abundance, the spot will be green, if the RNA from the 
amastigote, it will be red. If both are equal, the spot will be yellow, while if neither is 
present the spot will appear black. Thus, from the fluorescence intensities and colours 
for each spot, the relative translation levels of the genes in both samples can be 
estimated. More background information on DNA array technology can be found in 
[87], including several references to relevant websites. It is expected that the application 
of microarray technology in combination with the Leishmania genome project will 
allow the identification of many new drug and vaccine targets. Recently, Professor J.M. 
Blackwell reported at the Fourth TDR/IDRI meeting on second generation vaccines 
against leishmaniasis on the use of microarrays to identify potential new vaccine targets. 
DNA microarrays were used to simultaneously monitor the expression profiles for 2183 
unique Leishmania genes as the parasite undergoes developmental transition from the 
logarithmic promastigote to the metacyclic form and in the host derived amastigote 
form. From this analysis, more than 100 previously unknown genes were identified that 
are up-regulated in expression in amastigotes. These are now being tested as new 
vaccine candidates; some cocktails of them appear to be effective as DNA vaccines in 
mice. 
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1.7 RATIONALE: 
There is a need of sensitive molecular techniques for diagnosis of leishmaniasis. This is 
because serological tests show poor performances in HIV-co-infected patients as well as 
in clinical forms characterised by a Th1 answer, like cutaneous and mucocutaneous 
leishmaniasis. In these cases, first line diagnosis consists in parasitological detection. 
However, since parasitaemia can be extremely low and parasite detection tests can only 
be performed by trained personnel, quite a number of actually infected persons will 
remain untreated and will constitute a non-controlled human reservoir. 
There is need to develop tests that can be used to accurately distinguish different 
Leishmania species. This is because species identification is important for clinical and 
treatment purposes, epidemiological studies and disease control (anthroponoses versus 
zoonoses). In the clinical context, it is necessary to distinguish different species of 
Leishmania because they lead to different diseases (visceral leishmaniasis versus 
cutaneous leishmaniasis). Some species are also linked to more severe secondary 
pathology, such as post-kala-azar dermal leishmaniasis (PKDL) for L. donovani.  
L. major infection is self-curing. In addition, the response to treatment and drug 
resistance can also be species specific. For instance, L. tropica is poorly responsive to 
antimony. Epidemiologically, several species are often prevalent in the same country, 
but there are few or outdated distribution maps. Leishmania species repartition can 
change and should be monitored by passive diagnosis and determination of species for 
each patient. L. infantum is a zoonotically transmitted disease for which dog is the most 
important reservoir and host, while L. donovani is thought to be transmitted 
anthropozoonotically, which has important implications for prevention and control 
programmes.  
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 1.8 OBJECTIVES:  
 
 
1) To characterize Sudanese isolates of Leishmania by sequencing ITS1 regions. 
2) To evaluate the repeatability and reproducibility of NASBA-OC and PCR-OC 
for the diagnosis of VL in a multicenter ring trial. 
3) To validate the   PCR-OC and NASBA-OC for VL in a Phase 11 study in Sudan 
4) To evaluate the performance of the  PCR-OC and NASBA-OC for VL on 
Kenyan  samples: 
5) To develop standard operating procedure (SOP) for Leishmania ITS1 species 
specific PCR that distinguishes between old world species. 
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2. Materials and Methods 
This study is composed of five components: the first one was characterization of 
Sudanese isolates of leishmania, the second one was multicenter ring trial, the third one 
was phase II evaluation study on PCR-OC and NASBA-OC on Sudanese samples, the 
fourth one was phase II evaluation study on PCR-OC and NASBA-OC on Kenyan 
samples and the fifth one was Identification of Old World Leishmania species by 
specific PCR. 
2.1 CHARACTERIZATION OF SUDANESE ISOLATES OF LEISHMANIA:- 
2.1.1 STUDY DESIGN: 
This is a cross sectional study for typification of Sudanese isolates of Leishmania. 
2.1.2 STUDY AREA:  
The study was conducted between January 2007 and January 2008 in villages in Atbara 
River Area, Gedarif state-Eastern Sudan, a recognized endemic area for VL in the 
country [88].   
2.1.3 STUDY SUBJECTS: 
The study subjects included VL suspects (fever for more than 2 weeks and 
splenomegally and / or lymphadenopathy) and PKDL cases (nodular, ulcerative or 
noduloulcerative lesions) as described by Zijlstra and El-Hassan [19] 
2.1.4 SAMPLE SIZE: 
A total of 22 Leishmania isolates were included in the study: 20 isolates from VL 
clinical cases and 2 from PKDL cases. 
2.1.5 RESEARCH ETHICS: 
Informed consent was obtained from all patients to participate in this study. Ethical 
clearance for the study was obtained from the National Ethics Committee of the Federal 
Ministry of Health in Sudan and of the University of Antwerp in Belgium.  
2.1.6 STUDY DESCRIPTION AND PROTOCOLS: 
2.1.6.1: THE FIELD WORK: 
The field work involved the selection of VL and PKDL cases as described previously 
and the primary isolation of leishmania.  
2.1.6.1.1: PARASITOLOGICAL TECHNIQUES: 
Direct microscopy: 
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Slit smears (PKDL) or needle aspirations (VL) were done on suspect cases and part of 
the material were smeared on a clean glass slide, fixed in methanol and stained with 
Giemsa′s stain for the detection of amastigotes. 
Lymph node aspiration: 
An enlarged lymph nodes in case of VL suspect were selected (the inguinal nodes are 
the most convenient), after cleaning the skin the needle (without the syringe) was 
inserted, rotated gently and part of the fluid was expelled on a clean glass slide 
Bone marrow aspiration: 
The superior posterior iliac crest was mostly selected for bone marrow aspiration and 
part of marrow was pushed on a clean glass slide 
Skin slit smear: 
The affected site, e.g. a papule or nodule, was cleaned and pressed firmly between 
thumb and finger to avoid contamination with blood. The surface of the lesion was cut 
with a surgical blade which was then turned through 90” and material is collected by 
Scraping and part of them applied to a slide 
Invitro culture of leishmania parasite:- 
The remaining of the materials described above was inoculated in use of Tobie blood 
agar media (Tobie EJ, 1949). The cultures were incubated at 26 oC and transported in 
this temperature to the central lab in Soba University hospital and checked for after 4-14 
days for the presence of promastigotes. Locke solution, usually in the amount of 0.5 –2 
ml, was used as overlay fluid to support the growth of the parasites in the Tobie culture 
medium. Antibiotics were added to the Locke solution to reduce the risk of 
contamination of the medium by the other unwanted micro-organisms. Penicillin and 
Gentamicin were used for the primary isolation and Penicillin and Streptomycin for 
maintenance. The parasites were checked twice per week for viability and density and a 
copy of those strains were taken to the Institute of Tropical Medicine (Antwerp). 
2.1.6.2: MOLECULAR CHARACTERIZATION OF SUDANESE ISOLATES:-  
This work was carried out at the Institute of Tropical Medicine, Antwerp. The work   
involved subculture of the isolates in Tobies medium with Locks solution as an overlay; 
the cultures were maintained until the density of the promastigotes reached about 
106/ml. Then part of the parasites were cryopreserved by adding them to a mixture of 
30% glycerol and PBS in a ratio of 3:1 to make stabilates which were kept in liquid 
nitrogen or in -70 oC. The rest of the lock solution were filtered and washed with PBS 
and centrifuged to get the parasite pellet.  
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2.1.6.2.1 DNA EXTRACTION OF PARASITES PELLETS: 
The DNA extraction was carried out using QIAamp Mini Kit; Germany (catn°51304). 
The parasites pellets were resuspended in PBS to a final volume of 200 µl. Then 20 µl 
QIAGEN Protease or Proteinase K were added. 200 µl AL (lysis buffer) was added to 
the sample and mixed well, incubated at 56°C for 10 min (to reach a maximum DNA), 
centrifuged in   1.5 ml microcentrifuge tube. And 200 µl ethanol (96–100%) was added 
to the sample, and mixed again and briefly centrifuged. The mixture was carefully 
applied to the QIAamp Spin Column (in a 2 ml collection tube) and centrifuged at 6000 
x g (8000 rpm) for 1 min and the QIAamp Spin Column placed in a clean 2 ml 
collection tube, and the tube containing the filtrate was discarded. Then 500 µl of the 
AW1 buffer was added and centrifuged at 6000 x g (8000 rpm) for 1 min and the 
QIAamp Spin Column placed in a clean 2 ml collection tube, and the tube containing 
the filtrate was discarded. This was followed by the addition of 500 µl of the AW2 
buffer and centrifugation at 20,000 x g; (14,000 rpm) for 3 min. Then the QIAamp Spin 
Column was placed in a clean 1.5 ml microcentrifuge tube and the collection tube 
containing the filtrate was discarded then 200 µl Buffer AE or distilled water was added 
and incubated at room temperature (15–25°C) for 5 min, and centrifuged at 6000 x g 
(8000 rpm) for 1min. 
2.1.6.2.2 TYPING OF SUDANESE LEISHMANIA ISOLATES BY SEQUENCING 
ITS1 REGIONS: 
The internal transcribed spacer 1 of the ribosomal DNA repeat unit (rDNA-ITS1)  
as shown in Fig 2.1 was amplified with primers (rDNA-10F and rDNA-14R) 
(5’ CAATACAGGTGATCGGACAGG 3’) and (5’ CACGGGGATGACACAATAGAG 3’). 
The primers concentration was 0.5 µM and they were ordered from Sigma-Aldrich 
(Bornem, Belgium). The total reaction volume was 50 µl of 1x PCR buffer (Qiagen, 
Venlo, The Netherlands), including 1mM of MgCl2 buffer (Qiagen, Venlo, The 
Netherlands), 200 µM of each dNTPs from Eurogentec (Seraing, Belgium) and 1 unit 
HotStarTaq Plus DNA polymerase (Qiagen, Venlo, The Netherlands) was used to give 
0.02 u/ul concentration in the final PCR mix, 1 ul of extracted DNA from promastigote 
cultures added to the mix. The PCR mix was supplemented in a 200µl tube or plate. 
Cycling conditions for  PCR were : 5 min at 95°C; followed by 40 cycles of 30 sec 
94°C, 30 sec 60°C, and 45 sec 72°C; and finally 5 min at 72°C. The PCR was 
performed in an Eppendorf EP Gradient S (Eppendorf, Wesseling-Berzdorf, Germany) 
thermocycler. 5 µl of the products were analyzed on a 2% agarose gel stained with 
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ethidium bromide, and scored positive when an amplicon of the expected size was 
observed (500bp). The remaining PCR products (45 µl) were sent to Antwerp 
University centre for automated sequencing. The results of sequencing are analyzed by 
Invitrogen (Vector NTI) program and compared to reference ITS1 sequence, the 
determined rDNA-ITS1 sequences were submitted to the EBI sequence data base. 
Further more to differentiate between L.donovani and L.infantum within the L.donovani 
complex the following PCR protocols were used:- 
2.1.6.2.3 LEISMANIA CYSTEINE PROTEINASE B SPECIES-SPECIFIC PCRs: 
These PCR assays [89] were used to differentiate between Leishmania donovani and 
Leishmania infantum species of the L.donovani complex that had been confirmed by 
ITS1 sequencing PCR protocol. They were performed in 30 ul containing 1.5 U 
HotStarPlusTaq DNA polymerase (Qiagen, Venlo, The Netherlands) and the 
accompanying 1x HotStarPlusTaq buffer (including 1.5 mM MgCl2); 0.2 mM of each 
dNTP; 0.33 uM of each primer:  
cpbF2.1(5’GCGGCGTGATGACCAGC3’)cpbDo2.1(5’CAATAACCAGCCATTCGTT
TTTA3’) for donovani species and  infcpbE (5’ TCTTACCAGAGCGGAGTGCTACT 
3’) cpb inf2.1 (5’ ATAACCAGCCATTCGGTTTTG 3’) for infantum species; and for 
each PCR mix 1 ul of extracted DNA from promastigote cultures was added.  
Cycling was done as follows: initial denaturation for 5 min at 95°C; 40 cycles 
consisting of 30 sec 95°C, 15 sec 59°C, 15 sec 72°C; and finally an extra elongation 
step of 5 min 72°C.   
 
Fig. 2.1.1 rDNA ITS1 sequencing 
5.8S rDNA (2348 - 2630) 
2100 2200 2300 2400 2500 2600 2700 
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rDNA 
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2.2. MULTICENTER RING TRIAL: 
This is the second component of the study which was carried out at the Department of 
Biochemistry, Faculty of Medicine and Soba University Hospital. It was a quality 
assurance, proficiency testing of the collaborating laboratories (see 2.2.1). The study 
involved the evaluation of repeatability and reproducibility of nucleic acid sequence-
based amplification with oligochromatography (NASBA-OC) and polymerase chain 
reaction with oligochromatography (PCR-OC) for the detection of Leishmania or 
Trypanosoma brucei. 
2.2.1 PARTICIPATING LABORATORIES: 
The ring trial was performed by trained persons in seven independent laboratories in six 
countries: Makerere University in Uganda, Institut National de Recherche Biome´dicale 
in Democratic Republic (DR) of the Congo, Kenya Medical Research Institute in 
Kenya, University of Khartoum in Sudan, The Koninklijk Instituut voor de Tropen 
Biomedical Research in The Netherlands, Coris BioConcept and the Institute of 
Tropical Medicine both in Belgium. The laboratories in Europe evaluated all four tests; 
the laboratories in Uganda and DRC evaluated the Tryp- PCR-OC and Tryp-NASBA-
OC and the laboratories in Kenya and Sudan tested the Leish-PCR-OC and Leish- 
NASBA-OC. All participants were trained in test execution during a one-week 
workshop held at Makerere University (Kampala, Uganda). 
2.2.2 SPECIMEN PREPARATION:  
In-vitro cultured Trypanosoma brucei gambiense (LiTat 1.3) and Leishmania donovani 
(MHOM⁄SD ⁄ 68 ⁄ S1) parasites were suspended in phosphate-buffered saline (PBS) at a 
concentration of 106 parasites per ml PBS. This suspension was used to prepare two 
different sets of specimens. The first set of specimens comprised serially diluted 
parasites in Tris-EDTA (TE) buffer containing 20 µg ⁄ ml calf thymus DNA to prevent 
degradation of the target DNA (dilution buffer) at concentrations of 100 000, 10 000, 
1000, 100, 10 and 0 parasites per ml. The second set comprised human blood from a 
healthy volunteer spiked with 1000, 100, 10 and 0 T. brucei gambiense or Leishmania 
parasites per ml of blood. All blood specimens were prepared in triplicate. Four blood 
specimens from non-endemic healthy volunteers were further included in the study as 
negative controls.  
2.2.3 TRANSPORTATION AND STORAGE OF SPECIMENS  
All specimens were prepared by a single individual in a central laboratory (The 
Koninklijk Instituut voor de Tropen Biomedical Research in The Netherlands), as 
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cooled transport to several participants could not be guaranteed, the blood specimens 
were stabilized on silica before shipment. This was carried out by performing the first 
step in the nucleic acid extraction protocol [90]. In brief, 200 µl of each specimen was 
mixed with 1.2 ml of L6 lysis buffer (50 mM Tris–HCl, 5M GuSCN 20 mM EDTA, 
0.1% Triton X100) and subsequently 40 µl of silica suspension was added and mixed 
for a further 5 min. The samples were centrifuged and the supernatant discarded, 
leaving behind a pellet of silica with bound nucleic acids. The specimen sets were 
shipped on dry ice to the various participating laboratories. All samples were coded and 
tested blindly by a trained person in each of the seven laboratories.  
2.2.4 EXTRACTION OF NUCLEIC ACIDS  
The silica pellet was washed twice with 1 ml of L2 wash buffer (5 M GuSCN, 100 mM 
Tris–HCl [pH 6.4] supplied by the central laboratory to trial participants), twice with 1 
ml of 70% ethanol, and once with 1 ml of acetone. The pellet was dried at 56 °C for 5 
min after which the nucleic acids were eluted in 50 µl TE buffer during 5-min 
incubation at 56 °C. The eluted nucleic acids were stored at -20 °C until amplification. 
2.2.5 STUDY PROTOCOL 
The Trypanosoma specimen set was analyzed with the Tryp-NASBA-OC and Tryps-
PCR-OC; while the Leishmania specimen set was analyzed with the Leish-NASBA-OC 
and Leish-PCR-OC. With the specimen set and necessary test reagents, the participating 
laboratories also received a test report sheet, questionnaire and standard operating 
procedures for nucleic acid extraction as described by Boom et al. [90], and the PCR-
OC and NASBA-OC execution protocols as described by Deborggraeve et al. [51, 52] 
and Mugasa et al. [55, 91]. The laboratories further purified the nucleic acids from the 
blood specimens and analyzed the blood specimens once and the nucleic acid dilutions 
in PBS thrice.  
2.2.5.1 PCR-OC AND NASBA –OC 
All specimens were tested blindly and test results were reported to the central laboratory 
for statistical analysis. 
2.2.6 STATISTICAL ANALYSIS 
Accordance (ACC), defined as the average chance of finding the same result for two 
identical specimens analyzed in the same laboratory, and concordance (CON), defined 
as the average chance of finding the same result for two identical specimens analyzed in 
different laboratories, of Tryp-PCR-OC, Tryp-NASBA-OC, Leish-PCR-OC and Leish-
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NASBA-OC were estimated in a random framework by the formulae described by van 
der Voet and van der Raamsdon [92]: 
ACCr = (1⁄L) ∑i (p0,i 2+p1,i 2) and CONr = P0 2+P1 2, in which p0, i 2and p1,i 2 were 
defined as the squared proportion of Tryp-PCR-OC, Tryp-NASBA-OC, Leish-PCR-OC 
and Leish-NASBA-OC negative and positive results, respectively, for each analysis i 
and where P0 2 and P1 2 were defined by the equations P0 2 = (1⁄L) ∑i  = 1 p0,i and P1 2 
= (1⁄L) ∑i = 1 p1,i with L the number of laboratories in the trial. Around the ACC and 
CON estimates, 95% confidence intervals (CI) were quantified by bootstrapping [93]. 
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2.3. LABORATORY EVALUATION (PHASE II STUDY) OF PCR-OC AND 
NASBA-OC USING SUDANESE SAMPLES: 
2.3.1 STUDY DESIGN AND SAMPLE SIZE: 
This is prospective study to evaluate PCR-OC and NASBA-OC tests on 90 confirmed 
and 90 suspected VL cases, 7 confirmed and 8 suspected CL cases, 2 confirmed PKDL 
cases and 50 healthy endemic controls. 
2.3.2 PARTICIPANTS 
VL suspects, PKDL suspects and endemic healthy controls were recruited in Gedarif 
State and CL in Khartoum State between October 2008 and January 2009. VL and 
PKDL suspects were recruited in the health centers of villages within the endemic areas 
while the endemic healthy controls were volunteers from the same villages but not 
visiting the health centers. CL suspects were recruited at the Dermatology Hospital in 
Khartoum. Confirmed leishmaniasis cases were given appropriate treatment in the same 
health center or hospital as they were diagnosed. A participant was included in the study 
if 2 years or older and written consent was obtained from the individual or his/her 
guardian. Specimen collection was performed by the Faculty of Medicine of Khartoum 
University. Ethical clearance for the study was obtained from the ethical committees of 
the Federal Ministry of Health Committee in Sudan and the University of Antwerp in 
Belgium. 
2.3.3 CLINICAL SCREENING: 
The criteria for clinical selection of VL suspect was based on the presence of fever for 
two weeks or more, splenomegaly and /or lymphadenopathy and exclusion of Malaria, 
Typhoid and Tuberculosis. The criteria for clinical selection of PKDL and CL suspect 
was based on the presence of  papular, nodular or ulcerative lesions on exposed areas of 
the skin . The demographic and clinical information was recorded in standard form. 
2.3.4 PARASITOLOGICAL DIAGNOSIS: 
The same procedure as described in 2.1.6.1.1 
2.3.5. COLLECTION OF SAMPLES: 
2.3.5.1 SAMPLE FOR NUCLEIC ACID 
Two hundred µl anti-coagulated blood (confirmed and suspected VL cases and healthy 
endemic controls), and/or lymph node, and/or bone marrow aspirate (confirmed and 
suspected VL cases) or lesion or nodule scrapings (confirmed and suspected CL and 
PKDL cases) was mixed with 200 µl of L3 buffer (the trade name AngeroNATM, from 
Mallinckrodt Baker (USA)) This buffer allows specimen storage without loss of DNA 
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and RNA quality. (Specimens were shipped at 4°C from the collection site to the central 
laboratory at Soba University Hospital laboratory, Khartoum University and stored at 
4°C for a maximum of two weeks. 
2.3.5.2. SAMPLE FOR DAT: 
From each healthy endemic control, (5ml) of venous blood sample was collected in 
EDTA container. (2ml) .Serum was transferred to (5ml) eppendorf tube and were 
shipped at -70°C (liquid nitrogen) from the field collection site to the central laboratory 
at Soba University Hospital, Khartoum University and stored at -20 oC for DAT. 
2.3.6. THE DIRECT AGGLUTINATION TEST (DAT): 
The DAT was performed essentially as described by Harith et al [94]. The wells of the 
V-shaped micro-titre plates were filled with the serum dilution fluid. First well (of a 
row): 100 µl dilution fluid and all other wells (of a row): 50 µl dilution fluid then1 µl 
serum was added to the first well of a row (the first dilution is 1:100), the serum was 
diluted by using a multi-channel pipette and Well 12 was used as a negative control well 
then the plate was covered and incubated overnight, finally the titer was defined as the 
highest dilution at which agglutination was still visible. In comparison to the blue dots 
present in the negative control wells, this agglutination shows as blue mats, enlarged 
blue dots with frayed edges, or enlarged blue dots  
2.3.7 Participant classification and reference tests 
A participant was classified as (i) confirmed VL case if there was clinical suspicion for 
VL, DAT on serum was positive (titer ≥ 1:3200) and parasites were observed in lymph 
or bone marrow aspirates by microscopic analysis; (ii) suspected VL case with positive 
DAT if there was clinical suspicion for VL, DAT on serum was positive, no parasites 
were observed in lymph or bone marrow aspirates and no previous history of VL was 
reported; (iii) suspected VL case with negative DAT if there was clinical suspicion for 
VL, DAT on serum was negative, no parasites were observed in lymph or bone marrow 
aspirates and no previous history of VL was reported; (iv) endemic healthy control if 
there was no clinical suspicion for VL, no previous history of VL and DAT on serum 
was negative; (v) confirmed CL or PDKL case if there was clinical suspicion for CL or 
PKDL and parasites were observed in lesion or nodule scrapings by microscopic 
analysis; and (vi) suspected CL case if there was clinical suspicion for CL and no 
parasites were observed in lesion or nodule scrapings. Clinical suspicion for VL was 
defined as a history of fever for two weeks or more and splenomegaly or 
lymphadenopathy and for CL and PKDL the presence of skin lesions or nodules. The 
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reference tests were performed by experienced laboratory technicians immediately after 
specimen taking at the collection sites as described in the WHO manual on visceral 
leishmaniasis [95]. 
2.3.8 PCR-OC AND NASBA-OC TESTS: 
This work was done at the Department of Biochemistry, Faculty of Medicine and Soba 
University Hospital. Nucleic acids of the specimens were extracted according to the 
method described by Boom et al. [90]. Elution was done in 50 µl of pure water or Tris-
EDTA (TE) buffer and stored at -20°C until analysis. The extracts were tested with the 
Leishmania OligoC-TesT and NASBA-OC between October 2008 and February 2009 
as described by Deborggraeve et al. [52] and Mugasa et al. [55]. In brief, with the 
OligoC-TesT DNA of the parasite is amplified by PCR and subsequently 40 µl of 
denatured PCR product is mixed with 40 µl of migration buffer preheated at 55°C for at 
least 20 minutes followed by dipping the Oligo-strip into the solution. The NASBA-OC 
amplifies an RNA sequence of the parasite by NASBA reaction after which 4 µl of the 
amplified product is mixed with 76 µl of migration buffer preheated at 55°C and the 
Oligo-strip is dipped into the solution. Test results are read after 10 minutes for both 
tests. Training on PCR-OC and NASBA – OC had been received during a one-week 
workshop held in June 2007 at Makerere University, Kampala, Uganda. No external 
quality control confirming the reference test or index test results could be performed 
during the study.  
2.3.9 Data analysis 
The sensitivity and specificity of the Leishmania OligoC-TesT and NASBA-OC were 
calculated from data entered into contingency tables. Differences in sensitivity and 
specificity between the two tests and differences in test results of specimen types were 
estimated by the Mc Nemar test. Concordances between the two tests were determined 
using the kappa index. All calculations were estimated at a 95% confidence interval 
(95% CI). 
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2.4. LABORATORY EVALUATION OF PCR-OC AND NASBA-OC TESTS ON 
KENYAN SAMPLES: 
Sample collection and Nucleic acid extraction was performed at KEMRI in Kenya 
within 2 weeks of arrival of the specimen from the collection site. The extracts were 
analyzed with the PCR- OC and NASBA -OC between October 2008 and February 
2009 at Soba University hospital, Khartoum University in the frame of a collaborative 
consortium.  
All the samples were tested with the Leishmania OligoC-TesT and NASBA-OC as 
described by Deborggraeve et al. [52] and Mugasa et al. [55]. Test kits were provided 
by Coris BioConcept (Gembloux, Belgium). In brief, the Leishmania OligoC-TesT 
amplifies a short sequence of the Leishmania 18S ribosomal DNA by PCR, and the 
NASBA-OC amplifies a part of the 18S ribosomal RNA by NASBA. For both assays, 
the amplification products are mixed with migration buffer preheated to 55 °C after 
which the dipstick is dipped into the solution. Migration is performed at 55 °C, and test 
results are read after 10 min. The two tests contain internal controls to validate the 
migration as well as the amplification reaction. 
2.4.1 DATA ANALYSIS 
The sensitivity and specificity of the Leishmania OligoC-TesT and NASBA-OC were 
calculated from data entered into contingency tables. Differences in sensitivity and 
specificity between the two tests were estimated by the McNemar test. Concordances 
between the two tests were determined using the kappa index. All calculations were 
estimated at a 95% confidence interval (95% CI). 
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2.5. IDENTIFICATION OF OLD WORLD LEISHMANIA SPECIES BY 
SPECIFIC PCR AMPLIFICATION OF RDNA ITS1: 
2.5.1 DNA SAMPLES: 
DNAs from reference strains and isolates were obtained from cultured parasites, and 
were either grown and extracted at the Institute of Tropical Medicine Antwerp (ITMA, 
Antwerp, Belgium), or kindly donated by several institutes acknowledged at the end of 
this manuscript. Concentration of the parasite DNA was measured using the Nanodrop 
ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA). 
Isolates were characterized by rDNA-ITS1 sequencing, or a discriminative PCR 
targeting cysteine proteinase B [89]. For sequencing, PCR amplicons (Fig. 2.5.1) were 
generated with primers rDNA-10F (5’ CAATACAGGTGATCGGACAGG 3’) and 
rDNA-14R (5’ CACGGGGATGACACAATAGAG 3’), and this was followed by direct 
sequencing without cloning. Table 2.5.1 lists the origin of all samples used during the 
evaluation and validation steps, and the accession numbers of the determined rDNA-
ITS1 sequences. The definitions of L. infantum and L. donovani are as in [96]. 
2.5.2 PRIMERS AND INTERNAL CONTROLS: 
Species-specific PCR primers were designed on the basis of an alignment of rDNA-
ITS1 sequences newly determined (Table 2.5.1) and downloaded from the EBI 
sequence data base (www.ebi.ac.uk). Several primer combinations per species were 
tested, and a final set (Fig. 2.5.1, Table 2.5.2) was selected for extensive optimization, 
evaluation, and validation experiments. For each of the 4 species-specific PCRs, 
internal positive control templates were developed (Figs. 2.5.2, 2.5.3). These internal 
controls are added to the respective PCRs, and upon successful amplification they show 
a product of about 100 bp longer than the Leishmania species-specific amplicon. Such 
internal control allows to check for correct PCR mix set-up, and sample inhibition. To 
obtain these internal controls, phage lambda DNA fragments were amplified with 
composite cloning primer pairs, each consisting of a 3’ lambda-specific segment with a 
Leishmania species-specific 5’ extension matching the PCR primers in (Table 2.5.2) 
The amplified phage lambda sequences were selected to have a base composition 
comparable to the respective Leishmania targets. The phage lambda amplicons, flanked 
by the Leishmania primer annealing sites, were cloned in vector pCR4-TOPO using a 
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TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA), and verified by sequencing 
(Fig. 2.5.2). 
 
2.5.3 SPECIES-SPECIFIC PCRs 
Five PCRs were used in this study, which are listed in (Table 2.5.2) and depicted 
schematically in (Fig. 2.5.1) The total reaction volume was 25 µl of 1x Coralload PCR 
buffer (Qiagen, Venlo, The Netherlands), including 0.1 mg/ml acetylated BSA 
(Promega, Madison, WI, USA), 200 µM of each dNTP supplemented with 400 µM of 
dUTP, in a 200µl tube or plate. Other components are listed in their respective 
concentration in Table 2.5.2, and HotStarTaq Plus DNA polymerase (Qiagen) was used 
in each case. PCR LT2 was not used in the evaluation and validation experiments. 
Primers were ordered from Sigma-Aldrich (Bornem, Belgium), dNTPs from Eurogentec 
(Seraing, Belgium), and dUTPs from Roche (Vilvoorde, Belgium). Cycling conditions 
for all PCRs were identical: 5 min at 95°C; followed by 40 cycles of 30 sec 95°C, 40 
sec 55°C, and 40 sec 72°C; and finally 5 min at 72°C. All PCRs were performed in a 
BioMetra T3000 thermocycler (BioMetra, Göttingen, Germany). Products were 
analyzed on a 2% or 2.5% agarose gel stained with ethidium bromide, and scored 
positive when an amplicon of the expected size (Table 2.5.2) was observed. 
2.5.4 OPTIMIZATION AND EVALUATION 
Following development of the PCR protocols, the detection limit of the PCRs was 
assessed by using 10, 1, 0.1, and 0.01 pg DNA from 5 different parasite isolates or 
strains from each species. This was repeated with the addition of DNA extracted from 9 
µl naive human blood in each PCR, for which 2.5 µl of 180 µl blood extract eluted in 50 
µl was added to the reaction. The discriminatory power for identifying the correct 
species was assessed using 100 pg of the DNAs listed in (Table 2.5.1). The optimal 
concentration of the recombinant internal control plasmids was determined as the lowest 
concentration that consistently amplified in repeated experiments, as tested at least in 
triplicate in a 10 fold dilution series, followed by further refining by using 4 
intermediate concentrations. Sensitivity of the internal control amplification to PCR 
inhibitors was tested by adding 0.01, 0.1, and 1% of SDS (Sodium dodecyl sulphate) to 
the reaction. 
2.5.5 VALIDATION AND IMPLEMENTATION 
For the purpose of validating the final PCR protocols, a blinded test panel was 
compiled, including the strains listed in Table 1. DNA from each strain was included 
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twice in the panel: once at an amount of 100 pg per PCR, and once at an amount of 0.2 
pg including a DNA equivalent of 1 µl naive human blood per PCR. In addition, the 
panel contained 3 negative controls and 3 naïve blood extracted DNAs as quality check 
for contamination and cross-reactivity. This makes a total of 90 samples, which were 
supplemented by 6 negative controls by the person performing the test. Positive results 
were considered valid if no contamination was observed in these 6 added negative 
controls, and an amplicon of the expected Leishmania size (Table 2.5.2) was obtained. 
Negative PCR results were valid if no product of the expected size was observed, and 
the internal control amplicon (Table 2.5.2, Fig. 2.5.2) was amplified (Fig. 2.5.3). In case 
one of these conditions was not met, the PCR was repeated. All PCR mixes were 
prepared in bulk, containing all reagents except polymerase and Leishmania template. 
They were stored at -20°C and when needed an aliquot was taken to which polymerase 
and templates were added. For the purpose of implementation in an endemic reference 
lab, the tests were transferred to the Kenya Medical Research Institute (KEMRI, 
Nairobi, Kenya), where PCR mixes were produced locally. The tests in KEMRI were 
performed by a different person as those at ITMA, but using the same blinded test panel 
DNA. 
2.5.6 CLINICAL SAMPLES (PHASE I STUDY): 
We tested our assays on various clinical samples, containing different species of 
Leishmania and other pathogens. L. donovani samples were obtained from blood, bone 
marrow, and lymph node of visceral leishmaniasis patients from Sudan. L. infantum 
samples were obtained from bone marrow of Italian visceral leishmaniasis patients, and 
spleen taken from Portuguese dogs suffering of canine leishmaniasis. L. major and L. 
tropica samples were obtained from skin lesions of cutaneous leishmaniasis patients in 
Tunisia and Kenya. In addition, our assays were performed on blood from patients 
suffering Plasmodium falciparum malaria (Uganda) and human African 
trypanosomiasis (Democratic Republic of Congo), and on sputum from tuberculosis 
patients (Democratic Republic of Congo). DNA from these samples was extracted using 
various methods. 
2.5.7 DETERMINATION OF THE CAUSATIVE LEISHMANIA SPECIES ON 
SUDANESE SAMPLES FROM CONFIRMED AND SUSPECTED VISCERAL 
LEISHMANIASIS (VL) PATIENTS (PHASE II STUDY): 
L. donovani complex assay was tested on confirmed (40 samples) and suspected (20 
samples) which were collected between October 2008 and January 2009 in the Gedarif 
state in Sudan. (Table 2.5.3 and 2.5.4), 200 uL of blood (confirmed VL), bone marrow, 
 29
or lymph node (suspected VL) were preserved in equal volume of L3 and DNA was 
extracted according to the method of Boom et al. [90]. DNA was eluted in 100 uL Tris-
EDTA (TE) buffer and stored at-20°C. 
 
Table 2.5.1 Origin of strains used for evaluation and validation: 
Species Country Evaluation a Validation a Accession numbers b 
 
 
L. aethiopica 
Ethiopia 
 
 
 
Kenya 
8                        
2 
8                     
2 
FN677344, FN677347, 
FN677348, FN677349, 
FN677350, FN677351, 
FN677352, FN677353, 
FN677354, FN677355, 
FN677356,  
 
FN677346 
 
L. donovani c 
Ethiopia  
India  
Kenya  
Sudan 
2  
2 
 
2 
2                     
 
1                     
3 
 
 
FN677363, FN677364 
FN677358, FN677359, 
FN677360, FN677361, 
FN677362 
 
Infantumc 
France  
Italy  
Malta  
Portugal  
Spain  
Sudan 
1                       
1                       
 
1 
3  
1                    
2                    
1 
 
 2 
1                
 
L. major Burkina Faso  
Israel  
Kenya  
Saudi Arabia  
Spain  
Sudan  
Tunisia  
USSR (former 
Sovjet Union)  
Uzbekistan  
 
 1  
1  
1  
1  
1  
1  
1  
1 
1 
 1  
1  
1  
1  
1  
1  
1  
1 
 
 
 
 
 
 
 
FN677342 
 
 
FN677357 
L. tropica 
 
Iraq  
Israel  
Kenya  
Palestinian 
territory  
USSR (former 
Soviet Union)  
1 
2  
4 
2 
 1  
1  
2 
2 
2 
1 
 
FN677341 
 
FN677343, FN677345 
a Where possible, different parasite strains were used for the evaluation and validation. 
b Accession numbers are listed according to species and origin, but are not always determined 
from the strains or isolates used for the evaluation and validation. 
c Species of the L. donovani complex (L. donovani and L. infantum) are defined as in [96].. 
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Table 2.5.2: Overview of species-specific PCRs a 
a Only reagents differing between the PCRs are listed. Common reagents in all PCRs (buffer, BSA, dNTPs, dUTP) 
are described in Materials and Methods. 
b These amplicon sizes can deviate with a few nucleotides depending on the exact strain or isolate. 
c Internal control constructs are depicted in Fig. 2, and the amount used in each PCR is given between brackets. The 
concentration of the internal control template was estimated spectrophotometrically using the Nanodrop ND-1000 
Spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA). 
d This is the final concentration used in the PCR, inclusive of the 1.5 mM already present in the Coralload PCR  
buffer. 
e Primer annealing positions are depicted schematically in Fig.2.5 1. 
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Table 2.5.3:  The clinical details of the Sudanese VL suspected samples. 
Serial No Patient code Type of sample 
1 01/SD/GED/SUSPECT/T0810 Lymph node aspirate 
2 05/SD/GED/SUSPECT/T0810 Lymph node aspirate 
3 08/SD/GED/SUSPECT/T0810 Lymph node aspirate 
4 12/SD/GED/SUSPECT/T0810 Lymph node aspirate 
5 16/SD/GED/SUSPECT/T0810 Lymph node aspirate 
6 17/SD/GED/SUSPECT/T0810 Lymph node aspirate 
7 23/SD/GED/SUSPECT/T0810 Lymph node aspirate 
8 24/SD/GED/SUSPECT/T0810 Lymph node aspirate 
9 55/SD/GED/SUSPECT/T0812 Lymph node aspirate 
10 56/SD/GED/SUSPECT/T0812 Lymph node aspirate 
11 14/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
12 18/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
13 26/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
14 28/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
15 29/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
16 30/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
17 31/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
18 32/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
19 37/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
20 38/SD/GED/SUSPECT/T0810 Bone marrow aspirate 
 
Table 2.5.4:  The clinical details of the Sudanese VL confirmed samples. 
Serial No Patient code Type of sample 
1 31/SD/GED/Hammad/T0811/VL Venous blood 
2 32/SD/GED/Hammad/T0811/VL Venous blood 
3 33/SD/GED/Hammad/T0811/VL Venous blood 
4 34/SD/GED/Hammad/T0811/VL Venous blood 
5 35/SD/GED/Hammad/T0811/VL Venous blood 
6 36/SD/GED/Hammad/T0811/VL Venous blood 
7 37/SD/GED/Hammad/T0811/VL Venous blood 
8 38/SD/GED/Hammad/T0811/VL Venous blood 
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Serial No Patient code Type of sample 
9 39/SD/GED/Hammad/T0811/VL Venous blood 
10 40/SD/GED/Hammad/T0811/VL Venous blood 
11 41/SD/GED/Hammad/T0811/VL Venous blood 
12 42/SD/GED/Hammad/T0811/VL Venous blood 
13 43/SD/GED/Hammad/T0812/VL Venous blood 
14 44/SD/GED/Hammad/T0812/VL Venous blood 
15 45/SD/GED/Hammad/T0812/VL Venous blood 
16 46/SD/GED/Hammad/T0812/VL Venous blood 
17 47/SD/GED/Hammad/T0812/VL Venous blood 
18 48/SD/GED/Hammad/T0812/VL Venous blood 
19 49/SD/GED/Hammad/T0812/VL Venous blood 
20 50/SD/GED/Hammad/T0812/VL Venous blood 
21 51/SD/GED/Hammad/T0812/VL Venous blood 
22 52/SD/GED/Hammad/T0812/VL Venous blood 
23 53/SD/GED/Hammad/T0812/VL Venous blood 
24 54/SD/GED/Hammad/T0812/VL Venous blood 
25 55/SD/GED/Hammad/T0812/VL Venous blood 
26 56/SD/GED/Hammad/T0812/VL Venous blood 
27 57/SD/GED/Hammad/T0812/VL Venous blood 
28 58/SD/GED/Hammad/T0812/VL Venous blood 
29 59/SD/GED/Hammad/T0812/VL Venous blood 
30 60/SD/GED/Hammad/T0812/VL Venous blood 
31 67/SD/GED/Hammad/T0812/VL Venous blood 
32 68/SD/GED/Hammad/T0812/VL Venous blood 
33 69/SD/GED/Hammad/T0812/VL Venous blood 
34 70/SD/GED/Hammad/T0812/VL Venous blood 
35 71/SD/GED/Hammad/T0901/VL Venous blood 
36 72/SD/GED/Hammad/T0901/VL Venous blood 
37 73/SD/GED/Hammad/T0901/VL Venous blood 
38 74/SD/GED/Hammad/T0901/VL Venous blood 
39 75/SD/GED/Hammad/T0901/VL Venous blood 
40 76/SD/GED/Hammad/T0901/VL Venous blood 
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Fig.2.5.1 Position of the species specific PCR relative to the first nucleotide of the 18S rDNA gene in 
chromosome 27 of L. major strain Friedlin (www.ebi.ac.uk), accession number CP000079, release 
102) Drown to scale .the 18S .ITS1 and 5.8S rDNA fragments are indicated on top, according to the 
current annotation .Primer as in table 2.5.2, and the annealing position of the 5’ base is indicated, 
also delineating the start and the end of each amplicon. As the annealing position of all primers is 
given in relative to L.major fragment sizes calculated from these don’t correspond to those 
indicated in table 2.5.2 except for L.major itself. 
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Fig.2.5 2. Overview of the 4 cloned PCR products used as internal controls (Table 2.5.2).  
These PCR products were cloned in the pCR4-TOPO vector 
(tools.invitrogen.com/content/sfs/vectors/pcr4topo_map.pdf), from which the cloning site sequence 
is shown below. Amplicons were inserted using the T: A overhang strategy and the orientation in 
the obtained plasmids is as shown in the figure. The internal phage lambda fragments are described 
in the grey boxes, with positions referring to accession J02459 (www.ebi.ac.uk, accession number 
J02459, release 102). The regions corresponding to the Leishmania species-specific primer 
sequences (Table 2.5.2) are indicated in the outlined boxes, with the arrows showing the 5’-3’ 
orientation. 
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Fig. 2.5.3. Agarose gel image of the Leishmania species-specific PCR products (L), and the same 
products with internal control amplicon (IC). The GeneRuler 100 bp DNA size marker (Fermentas, 
St. Leon-Rot, Germany) is depicted on the left (M), with indicated fragments of 100 (smallest 
fragment), 500 (brightest fragment), and 1000 (largest fragment) nucleotides. Expected sizes are 
shown in Table 2.5.2. 
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3. RESULTS 
3.1. TYPING OF LEISHMANIA STRAINS: 
Table 3.1.1 shows   the clinical details of the studied Leishmania isolates. All the 22 
isolates gave products of PCR amplicon of the expected size (500bp) (Figure 3.1.1).  
As shown in (Fig. 3.1.2), in rDNA ITS1 phylogeny, all strains belong to the L. donovani 
complex. All the 22 isolates gave products with L. donovani cpb PCR amplicon of the 
expected size (300bp) and did not give products of the expected size with L. infantum 
cpb PCR (Fig.3.1.3).  
An overview of the leishmania typing results is presented in (Tables 3.2.1) 
 Table 3.1.1 The clinical details of the studied Leishmania isolates. 
Number Code No. Disease 
1 Sidon-Ged/med7 VL 
2 Sidon-Ged 2 VL 
3 Sidon-Ged 4 VL 
4 Sidon-Ged 6 VL 
5 Sidon-Ged 11 VL 
6 Sidon-Ged 15 VL 
7 Sidon-Ged 23 VL 
8 Sidon-Ged 150 VL 
9 Sidon-Ged 151 VL 
10 Sidon-Ged 153 VL 
11 Sidon-Ged 154 VL 
12 Sidon-Ged 155 VL 
13 Sidon-Ged 156 VL 
14 Sidon-SEN 1 PKDL 
15 Sidon-SEN 6 VL 
16 Sidon-SEN 7 VL 
17 Sidon-SEN 8 VL 
18 Sidon-SEN 9 VL 
19 Sidon-SEN 10 VL 
20 Sidon-SEN 14 VL 
21 Sidon-SEN 15 VL 
22 Sidon-SEN 17 PKDL 
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Figure 3.1.1 ITS1 PCR reactions for sequencing (PCR 10F-14R) 
 
 
The ITS1 sequences of all the 22 isolates are identical. 
 
CGGTGTTTTATCCGCCCGAAAGTTCACCGATATTTCTTCAATAGAGGAAGCA
AAAGTCGTAACAAGGTAGCTGTAGGTGAACCTGCAGCTGGATCATTTTCCG
ATGATTACACCAAAAAAAACATATACAACTCGGGGAGACCTATGTATATAT
ATATATGTAGGCCTTTCCCACATACACAGCAAAGTTTTGTACTCAAAATTTG
CAGTAAAAAAAAGGCCGATCGACGTTATAACGCACCGCCTATACAAAAGCA
AAAATGTCCGTTTATACAAAAAATATACGGCGTTTCGGTTTTTGGCGGGGTG
GGTGCGTGTGTGGATAACGGCTCACATAACGTGTCGCGATGGATGACTTGG
CTTCCTATTTCGTTGAAGAACGCAGTAAAGTGCGATAAGTGGTATCAATTGC
AGAATCATTCAATTACCGAATCTTTGAACGCAAACGGCGCATGGGAGAAG 
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  Figure 3.1.2 rDNA ITS1 clustering (Sudanese strains with bold) 
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  Figure 3.1.3 Cysteine proteinase B species-specific PCRs 
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Table 3.1.2 Leishmania typing results 
Number Strain L.donovani cpb PCR rDNA-ITS1 phylogeny Disease 
1 Sidon-Ged/med7 Donovani Donovani complex VL 
2 Sidon-Ged 2 Donovani Donovani complex VL 
3 Sidon-Ged 4 Donovani Donovani complex VL 
4 Sidon-Ged 6 Donovani Donovani complex VL 
5 Sidon-Ged11 Donovani Donovani complex VL 
6 Sidon-Ged 15 Donovani Donovani complex VL 
7 Sidon-Ged 23 Donovani Donovani complex VL 
8 Sidon-Ged 150 Donovani Donovani complex VL 
9 Sidon-Ged 151 Donovani Donovani complex VL 
10 Sidon-Ged 153 Donovani Donovani complex VL 
11 Sidon-Ged 154 Donovani Donovani complex VL 
12 Sidon-Ged 155 Donovani Donovani complex VL 
13 Sidon-Ged 156 Donovani Donovani complex VL 
14 Sidon-SEN 1 Donovani Donovani complex PKDL 
15 Sidon-SEN 6 Donovani Donovani complex VL 
16 Sidon-SEN 7 Donovani Donovani complex VL 
17 Sidon-SEN 8 Donovani Donovani complex VL 
18 Sidon-SEN 9 Donovani Donovani complex VL 
19 Sidon-SEN 10 Donovani Donovani complex VL 
20 Sidon-SEN 14 Donovani Donovani complex VL 
21 Sidon-SEN 15 Donovani Donovani complex VL 
22 Sidon-SEN 17 Donovani Donovani complex PKDL 
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3.2. MULTICENTER RING TRIAL: 
An overview of the test results at the different laboratories is presented in Tables3.2.1 
(Tryp-PCR-OC and Leish PCR-OC) and 3.2.2 (Tryp-NASBA-OC, and Leish-NASBA-
OC). 
Table 3.2.1 Results of Try and Leish PCR-OC tests on the specimen sets in the 
seven laboratories participating in the study 
 
 
The Leish-PCR⁄NASBA-OC results of one laboratory were excluded from the data 
analysis as unexplained high numbers of invalid results were observed at this 
laboratory, probably because of incorrect test execution. A test result is considered 
 42
invalid when both the test lines as the negative internal control line remain negative. 
ACC and CON were calculated for the four tests on the nucleic acids dilution series in 
PBS and on the parasite dilution series in blood separately and are presented in Table 
3.2.2 
Table 3.2.2 Results of Try and Leish NASBA-OC tests on the specimen sets in the 
seven laboratories participating in the study 
 
 
 
 
 
 43
Table 3.2.3 Overview of accordance and concordance of the Trypanzoon and 
Leishmania OligoC-TesT on DNA and blood specimens analyzed during the ring 
trial  
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3.3. Laboratory evaluation (phase II study) of PCR-OC and NASBA-OC using 
Sudanese samples: 
3.3.1 PARTICIPANTS 
In the study the following participants were recruited: 90 confirmed and 67 suspected 
VL cases with positive DAT, 23 suspected VL cases with negative DAT, 7 confirmed 
and 8 suspected CL cases, 2 confirmed PKDL cases and 50 healthy endemic controls. 
3.3.2 SENSITIVITY AND SPECIFICITY OF THE LEISHMANIA OLIGOC-
TEST AND NASBA-OC 
3.3.2.1 CONFIRMED VL, CL AND PKDL PATIENTS.  
The Leishmania OligoC-TesT and the NASBA-OC showed both a sensitivity of 96.8% 
on lymph node aspirates from confirmed VL cases and of 96.2% on blood (Table 3.3.1). 
The sensitivity on bone marrow was 96.9% and 95.3% for the OligoC-TesT and 
NASBA-OC, respectively. All confirmed CL (n= 7) and PKDL (n= 2) cases were 
positive with the OligoC-TesT and NASBA-OC. There was no significant difference in 
sensitivity between the two index tests (P.0.05). When analyzing different specimen 
types from the same VL patient we observed no significant difference in test outcome 
(P.0.05). 
3.3.2.2 SUSPECTED VL AND CL PATIENTS.  
On the suspected VL cases with positive DAT, the OligoC-TesT showed a positive test 
result in 37.1%, 76.9% and 72.7% on lymph, blood and bone marrow, respectively; 
while for NASBA-OC this was 34.3%, 69.2% and 63.6% (Table 3.3). On the suspected 
VL cases with negative DAT, the OligoC-TesT was positive in 30%, 28.6% and 42.9% 
on lymph, blood and bone marrow and the NASBA-OC in 30%, 42.9% and 50%. On 
the 8 CL suspected cases 7 were positive with the OligoC-TesT and the NASBA-OC. 
The Mc Nemar test indicated no significant difference in results of the two tests on the 
specimens from suspected cases (P.0.05). No significant difference was observed in test 
outcome when different specimen types from the same suspected VL patient were 
analyzed (P.0.05). Healthy endemic controls. Five of the 50 healthy endemic controls 
showed a positive OligoC-TesT result, while the NASBAOC remained negative on all 
endemic controls (Table 1). Hence, the specificity of the OligoC-TesT for disease was 
90.0% and of the NASBA-OC 100.0%, which is significantly higher (P, 0.05). Test 
agreement. On all specimens analyzed (n= 321) the two tests showed a kappa value of 
0.85 (95% CI: 0.75–0.96) indicating almost perfect agreement [97]. An overview of the 
agreement analysis on the different specimen types is presented in table 3.3.2. 
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Table 3.3.1 Diagnostic accuracy of leishmania OligoC-Test and NASBA-OC on 
confirmed and suspected leishmaniasis cases and on healthy endemic controls from 
Sudan 
 
 
Table 3.3.2 Agreement between the Leishmania OligoC-TesT and NASBA-OC on 
blood, lymph, bone marrow and lesion scraping specimens. 
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3.4. LABORATORY EVALUATION OF PCR-OC AND NASBA-OC TESTS ON 
KENYAN SAMPLES: 
3.4.1 PARTICIPANTS 
Eighty-four patients with VL and 98 endemic healthy controls were recruited in Baringo 
district in Kenya. An overview of the sensitivity and specificity of the OligoC-TesT and 
NASBA-OC on the study population is presented in Table 3.4. 
3.4.2 SENSITIVITY OF THE LEISHMANIA OLIGOC-TEST AND NASBA-OC 
The Leishmania OligoC-TesT and NASBA-OC on blood showed a positive test result 
in 81 and 67 of the patients with VL, respectively. Hence, the sensitivity of the 
Leishmania OligoC-TesT is 96.4% (95% CI: 90–98.8%) and of the NASBA-OC 79.8% 
(95% CI: 67–87%), which is significantly lower (P < 0.05). 
3.4.3 SPECIFICITY OF THE LEISHMANIA OLIGOC-TEST AND NASBA-OC 
Eleven out of 98 healthy endemic controls were positive with the Leishmania OligoC-
TesT, while no positive test results were observed with the NASBA-OC, indicating  
A specificity of 88.8% (95% CI: 81–93.6%) and 100% (95% CI: 96.3–100%), 
respectively. The McNemar test indicated a significant difference in specificity of both 
tests (P < 0.05). 
3.4.4 TEST AGREEMENT 
For the 182 blood specimens analyzed, the kappa index was 0.73 (95% CI: 0.59–0.87), 
indicating substantial agreement in results of the two index tests. 
Table 3.4.1 Diagnostic accuracy of leishmania OligoC-Test and NASBA-OC on 
confirmed VL cases and healthy endemic controls from Baringo district, Kenya 
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3.5 IDENTIFICATION OF OLD WORLD LEISHMANIA SPECIES BY 
SPECIFIC PCR AMPLIFICATION OF RDNA ITS1: 
3.5.1 SEQUENCES 
The determined rDNA-ITS1 sequences were submitted to the EBI sequence data base, 
and were assigned accession numbers listed in (Table 2.5.1) 
3.5.2. OPTIMIZATION AND EVALUATION 
Internal control templates and amplicons were successfully obtained and are depicted in 
Figs. 2.5.2 and 2.5.3. Their amplification was inhibited completely by 0.01% SDS, 
indicating their ability to detect PCR inhibitors. All PCRs showed the potential to 
amplify as little as 0.1 pg of DNA, which is about half a parasite’s genome. This 
detection limit was unaffected by the presence of DNA isolated from human blood, nor 
by the addition of the internal control template in its proper limiting concentration. For 
some DNA samples the detection limit was 1pg, for others it was possible to amplify 
0.01pg, variations probably caused by DNA degradation. No cross-reactivity of any 
specific PCR to other species was observed during the evaluation phase, except for 1 
out of 10 L. aethiopica DNAs that reacted in the LM PCR specific for L. major. 
3.5.3 VALIDATION 
Table 3.5.1 lists the results of a blinded panel validation, containing at least 10 isolated 
DNAs of each species or species complex. Results obtained at ITMA are given, as well 
as those obtained at KEMRI when discordant. In total 6 assays were included in the 
validation, both using 100 or 0.2 pg parasite DNA, the latter spiked with naïve human 
blood DNA. The 6 assays comprise the 4 species specific assays LA, LDI, LM, and LT1 
(Table 2.5.2) evaluated separately, but also as a combined tool (5th assay). In the 
separate evaluation, only the results of one PCR at the time are taken into account 
(positive or negative), while in the combined assay results from the 4 separate PCRs are 
considered simultaneously. In the latter case, a species will be assigned only if 1 out of 
4 PCRs scores positive, and is listed as undetermined if none or more than 1 PCR shows 
a positive result. The reason for evaluating the PCRs separately is that in reality it is 
unlikely that all 4 PCRs are performed on all samples, and more often than not a PCR 
will be used to confirm only the expected species. Finally, PCR LT2 makes up the 6th 
assay, which was performed following validation of the other assays because of a poor 
sensitivity of LT1. 
3.5.4 IMPLEMENTATION 
As a proof of principle to assess the performance when using the developed PCRs in 
another lab, the species-specific PCRs were implemented and validated at KEMRI, a 
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reference lab in Kenya, where leishmaniasis is endemic. Even though the same products 
and type of thermocycler were used, there was a problem in the amplification of the 
internal control amplicons, as well as with a slight contamination in the L. donovani 
complex PCR. This contamination showed a very faint PCR product and was visible in 
one out of the 6 user-added negative controls but in none of the negative controls of the 
blinded test panel. When ignoring these faint amplicons, and the fact that in many 
negative PCRs no internal control amplicon was amplified, the results were almost 
identical to those obtained at ITMA (Table 3). PCR LT2 (Table 2.5.2) was not tested in 
KEMRI. 
3.5.5 CLINICAL SAMPLE ANALYSIS (PHASEI) 
Fig. 3.5.1 depicts the results of 4 species-specific PCRs in clinical samples. The species 
could successfully be identified in the various Leishmania samples, as only one of the 4 
PCRs showed a Leishmania product of the correct size (Table 2.5.2). In all other cases, 
only the internal control amplicon amplified. In LT2, occasionally a weak PCR product 
is seen in samples not containing L. tropica, but this product is slightly smaller than 100 
bp, and clearly below the molecular weight of the product seen in the actual L. tropica 
samples. Equally so, a very weak amplicon is observed from the LA PCR in the left 
skin lesion scrapping L. tropica sample, but this is much fainter than the L. tropica 
amplicon. No products were amplified from patients suffering tuberculosis, sleeping 
sickness, or malaria. 
3.5.6 SENSITIVITY OF THE L. DONOVANI COMPLEX ASSAY -SPECIFIC 
PCR: 
3.5.6.1 SUSPECTED VL 
All the suspected VL cases showed a positive test result (100%) with L. donovani 
complex assay -specific PCR (Figure 3.5.2) 
3.5.6.2 CONFIRMED VL 
Thirty-nine patients out of the 40 confirmed VL cases showed a positive test result, a 
sensitivity of 97.5% with L. donovani complex assay -specific PCR (Figure 3.5.3). 
In figure (3.5.3) sample 32 (pointed with the arrow) gave invalid result firstly (no 
internal control band) and when it was repeated in (figure 3.5.2) it gave negative result 
with internal control band (pointed with the arrow).  
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Table 3.5.1: Overview of blinded panel validation result 
 
a   Negatives are TE in the 100 pg panel, naïve human blood in the 0.2 pg panel. 
b   The geographic origin of the isolates and strains is listed in Table 2.5.1. 
c   See Table 2. For each PCR assay, the number of positive PCRs per species or negative 
sample type is given. 
d   When there was no agreement between the numbers for the ITMA and KEMRI validation, 
the KEMRI result is given between brackets. 
e   For the combined assay, the number of correctly and wrongly identified isolates from each 
species is listed, as determined from a parallel evaluation of LA, LDI, LM, and LT1 PCRs. 
f   The LT2 PCR was not tested in KEMRI, and was not taken into account in the combined 
assay. 
g  The L. aethiopica isolate MHOM/ET/67/L86 was identified as L. tropica. 
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Fig. 3.5.1. Results from 4 species-specific PCRs on clinical samples. The PCRs are indicated on the 
left, as in Tables 2.5.2 and 3.5.1. Species in the clinical samples are depicted on top, as well as the 
type of sample analyzed. Only the agarose gel region between 100 and 400 bp is shown, as indicated 
by the size marker fragments identified between the left and right gel. The size of the amplified 
internal control and Leishmania fragments is as in Table 2.5.2 and Fig. 2.5.3, and is respectively 
indicated by white and black arrows on the right. 
 
 
 
 
Figure 3.5.2: L. donovani complex -specific PCR on VL suspected samples. 
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Figure 3.5.3: L. donovani complex -specific PCR on VL confirmed samples. 
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4.1 DISCUSSIONS 
4.1.1 CHARACTERIZATION OF SUDANESE ISOLATES OF LEISHMANIA: 
Identification of Leishmania species is important since they differ in transmission 
patterns, pathology and sensitivity to drugs [98, 99]. 
In this study two molecular methods were used to characterize 22 leishmania isolates. 
These molecular methods are based on the polymerase chain reaction (PCR) 
amplification of a Leishmania DNA fragment and they have advantages over multi-
locus enzyme electrophoresis, the current gold standard for species discrimination [57], 
the later one is a cumbersome technique requiring mass parasite cultivation.  
The first PCR assay amplified the ITS1 region followed by sequencing. All isolates 
even the two from PKDL lesions gave almost identical nucleotides sequence on 
analysis; all belong to L.donovani complex when compared to reference sequences. In 
agreement with previous studies [100, 22] L. donovani is also the causative species of 
both VL and PKDL.  
No diversity was observed in this ITS1 region for 10 isolates from Kenyan VL clinical 
samples. They differed only in one nucleotide position when compared to the Sudanese 
isolates. This may indicate homology in this ITS1 region for L.donovani from east 
Africa although the number of leishmania isolates is limited in this study. Due to the 
conserved sequences in this region for L.donovani and L.infantum, this PCR assay can 
not differentiate between the intra- species within the L.donovani complex. As this 
region has the advantage of having multiple copies in the genome, detection of the 
parasites in clinical samples, as will be mentioned later (Part 5 in this thesis), is 
possible. On the other hand, differentiation between L.infantum and L.donovani within 
the donovani complex was possible when the cysteine proteinase B species-specific 
PCR assays were used in the present and previous [89] studies. ; All isolates including 
the Kenyan ones are L.donovani and not L.infantum. However, this PCR assay can not 
detect the parasites genome in clinical samples and therefore it is used only on DNA 
from culture [89] which could be regarded as a disadvantage of the test.       
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4.1.2 MULTICENTER RING TRIAL: 
The evaluation of molecular diagnostics (and even diagnostics in general) is not always 
done. It is important to estimate the repeatability (ACC) and reproducibility (CON) of a 
new test prior to further phase II and III evaluation studies (which should be performed 
in other laboratories than the laboratory where the test was developed). The present 
study reports on a multi-centre evaluation study of two molecular assays in seven 
laboratories on two continents. Our study’s set-up and data analysis are of interest of 
many researchers working on diagnostic test development. The presented work can be 
an example for researchers wishing to develop new diagnostics for neglected tropical 
diseases, and it highlights some parameters that warrant control. Our main aim was to 
validate inter (ACC) and intra (CON) laboratory performance of the Tryp-PCR-OC, 
Tryp-NASBA-OC, Leish-PCR-OC and Leish-NASBA-OC tests. When analyzing 
purified nucleic acid specimens, the four tests showed an ACC and CON above 95% 
and 90%, respectively. The ACC and CON were below 90% when blood specimens 
were analyzed. This is not surprising as the nucleic acids had to be extracted from the 
blood specimens by the participating laboratories, leading to higher chances of intra and 
interlaboratory inconsistencies. In addition, the variation in test results was 
predominantly observed in the low parasite range of 1–0 parasites ⁄ ml blood. As this 
parasite concentration is close to the analytical sensitivity of the tests (Deborggraeve et 
al. [51, 52]; Mugasa et al. [55, 91], slight variations in equipment and operating 
procedures may have a major influence on the results obtained with these low parasite 
concentrations. Occasional false positive results were observed in the blood specimens 
from healthy European controls. Although cross-reaction of the tests with human DNA 
or RNA cannot be excluded, carry-over contamination during DNA extraction from the 
blood specimens is more likely for two reasons. First, no false positive results were 
observed in the specimen sets containing DNA. Secondly, there is the observation that 
three of the five false positive results for DNA were obtained in the same laboratory. 
The results of one laboratory analyzing the Leish-PCR⁄ NASBA- OC tests had to be 
excluded because very high numbers of invalid results were generated, most probably 
because of faulty test execution. Similar problems were not encountered at the other 
laboratories. To our knowledge, this is the first study evaluating the ACC and CON of 
molecular diagnostic tests for human African trypanosomiasis and leishmaniasis on 
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blood samples. The ACC and CON of the Tryp-PCR-OC have already been estimated 
in a multicentre ring trial with six participating laboratories on purified DNA 
specimens, reported by Claes et al. [101]. In that study, the test showed an ACC of 
88.7% (95%CI: 84.4%-92.5%) and CON of 88.1% (95%CI: 84.3%-92.3%), slightly 
lower than the results obtained in this study. 
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4.1.3 LABORATORY EVALUATION (PHASE II STUDY) OF PCR-OC AND 
NASBA-OC USING SUDANESE SAMPLES: 
Molecular diagnostics are attractive alternatives to conventional parasite detection as 
they combine sensitivity with specificity. Recently, the Leishmania OligoC-TesT and 
NASBA-OC were developed as standardized formats for molecular detection of 
Leishmania parasites [52, 55]. Here phase II evaluation of the two tests is presented on 
confirmed and suspected VL, CL and PKDL cases and on health endemic controls from 
Sudan. Although the study was set out as a phase II diagnostic evaluation, it has some 
limitations. A weak point is the lack of external quality control on a subset of specimens 
carried out by another reference laboratory. Furthermore, the executors of the index 
tests were not blinded to the participant classification and thus the results of the 
reference tests. Although these limitations did not influence the study results, these 
shortcomings should be avoided in future phase II and III evaluation trials. In addition, 
response to treatment was not included in the standard references as we were not able to 
follow up the patients after treatment. Lastly, the number of participants in some 
subgroups is too low to make major conclusions. The Leishmania OligoC-TesT as well 
as the NASBA-OC showed a high sensitivity (.95%) on lymph, blood and bone marrow 
from the confirmed VL patients. The observation that analyzing lymph or blood yielded 
similar sensitivity as bone marrow is very promising towards less invasive diagnosis. 
Indeed this means that the OligoC-TesT and NASBA-OC on lymph or blood could 
indicate the infection status of VL suspected cases. Similar findings were reported in a 
study on the phase III evaluation of conventional PCR for VL diagnosis in Nepal [102]. 
Although the number of confirmed CL and PKDL cases in this study was limited, all 
were positive with both tests indicating their potential for accurate detection of the 
parasites in skin tissues. In addition, the high sensitivity is confirmed by the observation 
that the tests were able to detect Leishmania RNA or DNA in the blood or lesion 
scrapings of to the majority of the suspected VL and CL cases. Several cases in the 
suspected patient with positive DAT group might be true leishmaniasis cases given the 
suboptimal sensitivity of the conventional parasite detection tests. In 2008, 
Deborggraeve et al. reported a sensitivity of conventional PCR on probable VL cases 
(defined as clinical suspicion of VL and positive DAT test but negative in conventional 
parasite detection) of 67.6% on blood and 71.8% on bone marrow [102]. The 
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sensitivities of the index tests on the lymph node aspirates of the suspected VL cases is 
surprisingly low (34–37%). This might indicate that the parasite load in blood is higher 
than in lymph. The fact that this is not observed in the confirmed VL cases is probably 
due to the general higher parasite load in this patient group because of the low 
sensitivity of the reference test. PCR positivity in the suspected VL group with negative 
DAT was not significantly lower than with positive DAT. This confirms the low 
correlation in DAT and PCR status in these groups as observed earlier [102]. While 
antibody levels in the blood are a marker for the host response, the PCR/ NASBA status 
of the blood is a marker for the presence of parasites and might therefore be 
complementary. PCR and NASBA can offer an added value compared to 
immunodiagnosis in HIV co-infected VL patients. 
On the 50 healthy endemic controls, the OligoC-TesT showed a specificity of 90% 
while this was 100% for the NASBA-OC. The positive OligoC-TesT results might be 
due to asymptomatic infections, which are known to be common in VL endemic 
regions. The inclusion of these asymptomatic carriers in the control group could be 
explained by the low concordance between negative DAT status and PCR outcome on 
blood from endemic control persons as described by Deborggraeve et al. [102] and 
Bhattarai et al. [103]. However, while NASBA-OC showed equal sensitivity on the 
confirmed and suspected VL cases, the test did not detect these assumed asymptomatic 
infections in the endemic control group. This discrepancy can be explained in two ways. 
Firstly, although not indicated by the negative controls taken along in specimen 
analysis, contamination of the PCR can never be fully excluded. Secondly, the OligoC-
TesT might be slightly more sensitive than the NASBA-OC and thus pick up 
asymptomatic infections which might have very low parasite loads in the blood.  
The observed equal sensitivity for both tests on the confirmed and suspected VL cases 
might be biased by the fact that these cases are individuals presenting syndromes and 
thus probably have higher parasite loads than healthy parasite carriers. Hence, NASBA-
OC might provide a better marker for active disease than the OligoC TesT, as NASBA-
OC does not detect asymptomatic infections while more than 95% of the active VL 
cases are still positive with the test. Furthermore, both tests might be useful as a test of 
cure after treatment of VL. As cure does not always equal parasite clearance, NASBA-
OC might be more suitable than the OligoC-TesT. However, specific evaluation studies 
are needed to confirm this hypothesis. One should keep in mind that the PCR-OC and 
NASBA-OC are not yet an option for routine diagnosis at the primary care level as they 
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require basic molecular biology lab facilities. VL typically affects populations in rural 
areas where health centers most often suffer from infrastructural limitations and thus 
only apply less sophisticated diagnostic methods. Yet, they can be valuable tools in 
leishmaniasis diagnosis at reference hospitals with basic molecular biology lab 
facilities. In addition, the evaluated tools can offer an added value in disease 
surveillance and epidemiological studies in which specimens are analyzed at central 
reference laboratories. 
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4.1.4 LABORATORY EVALUATION OF PCR-OC AND NASBA-OC TESTS ON 
KENYAN SAMPLES: 
When analyzing blood from the confirmed VL cases, a significantly higher sensitivity 
of the Leishmania OligoC-TesT (96.4%) was observed than the NASBA-OC (79.8%). 
As VL diagnosis was confirmed by microscopic analysis of spleen aspirates, the high 
sensitivity of the OligoC-TesT on blood is promising. Indeed, this means that the 
OligoC-TesT on blood could indicate the infection status of VL-suspected cases. Our 
findings are in agreement with the sensitivities shown by conventional PCR techniques 
for Leishmania, which generally range from 92% to 100% [104, 105, 106]. The lower 
sensitivity of NASBA-OC was unexpected because this test showed similar sensitivity 
as the OligoC-TesT in a multicentre evaluation study on Leishmania parasite-spiked 
blood [107]. The lower sensitivity observed in the current phase II study might be 
because of the fact that NASBA-OC targets the parasite’s RNA, which is known to be 
more liable to degradation compared to DNA. Nucleic acid quality might have been 
decreased during specimen storage and transportation from the collection sites in the 
field to the reference centre in Nairobi. In contrast, the NASBA-OC showed a 
significant higher specificity than the OligoC-TesT when analyzing blood from the 
healthy endemic controls (100% vs. 88.8%). Because the controls taken along during 
specimen analysis did not indicate contamination of the PCR based OligoC-TesT, the 
detection of Leishmania DNA in this control group is probably associated with 
asymptomatic Leishmania infections, which are known to be common in VL endemic 
areas [102, 103]. The inclusion of healthy parasite carriers in the control group can be 
explained by the low concordance between negative DAT status and PCR outcome on 
blood from endemic control persons, as described by Deborggraeve et al. [102] and 
Bhattarai et al. [103]. The observation that these healthy parasite carriers are not picked 
up by the NASBA-OC is probably because of its lower sensitivity, as reflected in the 
results on the confirmed VL cases. Patients with confirmed VL are individuals 
presenting symptoms and thus probably have higher parasite loads than asymptomatic 
parasite carriers. The sensitivity and specificity of both tests should also be evaluated in 
settings that do not need specimen storage and transport. It might be that in the present 
study, the sensitivity of the NASBA-OC is underestimated, and the specificity 
overestimated because of RNA degradation during specimen storage or transport. The 
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low specificity of the Leishmania OligoC-TesT in this study confirms that PCR-based 
diagnostic tests are a marker of infection rather than disease, as described by 
Deborggraeve et al. [102]. As only diseased persons are treated, PCR alone is of less 
value for VL diagnosis in endemic regions. However, one could state the same for 
diagnosis based on antibody detection tests alone or on clinical data alone because none 
of them represent a gold standard for acute disease. Hence, laboratory tests should 
always be interpreted in combination with a standardized clinical case definition. 
Although molecular diagnostics are not yet applicable in most operational settings 
because of their complexity, they can be useful in hospitals with basic molecular 
biology facilities. Molecular diagnostics should not replace the existing 
immunodiagnostics but give an added value as a marker of infection. 
It is important to emphasize that the Leishmania OligoC-Test and NASBA-OC are 
important steps forward to improved and standardised molecular detection of the 
parasite, but they are still restricted to use in reference centres with basic molecular 
biology facilities. Efforts towards further simplification of molecular diagnostics should 
therefore be strongly encouraged. In addition, although still to be confirmed by large-
scale studies, molecular detection of the parasite might be useful for cure assessment. 
While antibodies remain detectable for years after successful treatment [108], the 
parasite’s RNA and DNA are rapidly degraded following parasite death [109]. 
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4.1.5 IDENTIFICATION OF OLD WORLD LEISHMANIA SPECIES BY 
SPECIFIC PCR AMPLIFICATION OF RDNA ITS1: 
In this study 4 ITS1-rDNA PCRs are presented that can faithfully distinguish the Old 
World Leishmania species L. aethiopica, L. major, L. tropica, and the L. donovani 
species complex comprised of L. donovani and L. infantum. Because the number of 
sequences available for this region was limited for certain species, additional ones were 
added to the public repositories (Table 2.5.1). Compared to other assays devoid of post-
amplification steps other than agarose gel analysis (reviewed in [89]), this PCR assay 
has several advantages. (1) First, this assay is universally applicable in the Old World. 
Intra- and inter-species variability was validated by testing all species from diverse 
geographical origins (Table 2.5.1). It does not allow to differentiate L. infantum from 
other members of the L. donovani complex, for which alternatives are available [89, 
110-112]. (2) Second, the detection limit is sufficient to analyze clinical samples, as 
between 5 and 1/20 parasite genomes are amplifiable, and it showed amplification in 
actual clinical samples. (3) Third, these assays include dUTP, which allows to counter 
the effect of amplicon contamination using the dUTP/UNG system [113]. This can be 
particularly important in low resource settings, where basic precautions to avoid carry-
over contamination are often not easily adhered to, leading to false positive results. (4) 
Fourth, all 4 assays use the exact same thermal amplification conditions, which allows 
parallel analysis. As a bonus, PCR mixes containing all components except Leishmania 
template and enzyme can be stored at -20°C, facilitating batch quality control and 
saving time. (5) Fifth, internal controls allow checking for consistent amplification 
across different runs, and PCR sample inhibition [114]. Failure to amplify this control in 
a negative Leishmania sample points to the presence of inhibitors or an erroneously 
prepared PCR mix, in which case no conclusions must be drawn from the PCR. In a 
positive sample, it might simply indicate the Leishmania template out competes the 
control for primer annealing. (6) 
Finally, as illustrated in Fig. 2.5.1, these assays can be used as a nested PCR in case of 
insufficient sensitivity, whereby the Leishmania-specific primers LITSR and L5.8S 
[115] generate the outer PCR amplicons. In such case, all 4 specific PCRs must be run 
in parallel in the second PCR round to ensure specificity. As can be seen in Table 3.5.1, 
when taking results from the validation PCRs LA, LDI, LM, LT1, and the combined 
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assay, at the 100 pg level the species discrimination and identification performance is 
100%, except for L. aethiopica isolate MHOM/ET/67/L86 which cross-reacted in the 
LT1 PCR. Species identification of this isolate was however based on its unique 
zymodeme LON33 [116], and the rDNA-ITS1 region (accession FN677356) clearly 
showed an L. tropica sequence, explaining the positive amplification in the L. tropica 
PCR. Nevertheless, a limiting amount of L. aethiopica rDNA-ITS1 template is present 
in the DNA sample, as evidenced by the additional positive L. aethiopica PCR only at 
the 100 pg level, pointing to a hybrid strain or a mixed culture. The other PCRs showed 
no cross-reaction at the 0.2 pg level, but some isolates could not be identified. This was 
the case especially for L. tropica, where only 4 out of 10 DNAs could be typed. Given 
the fact that amplification failure may be caused by DNA degradation or mismatched 
primers, it is not surprising that some are not detected at the 0.2 pg level, corresponding 
to one parasite only. As the L. tropica PCR however identified merely 4 out of 10 L. 
tropica DNAs when supplied with 0.2 pg, an alternative PCR (LT2 in Table 2) was used 
including an outer Leishmania-specific DNA primer pair (Fig. 2.51, [115]) to boost the 
reaction. This allowed an additional 3 L. tropica to be identified from 0.2 pg, but 
resulted in an extra L. aethiopica DNA being detected (Table 3). LT2 must therefore be 
used only in parallel with PCRs LA, LDI, and LM. Upon evaluating the blinded test 
panel in an endemic reference center in Kenya, two problems were identified: the 
internal control amplicon did not amplify consistently, and a slight L. donovani 
contamination was observed in one out of six negative controls. Despite using the same 
products in the PCR mix, this illustrates the necessity to re-optimize the internal control 
template concentration during implementation. This becomes even more important 
when changing PCR reagents, such as the type of Taq DNA polymerase. Equally so, 
depending on the geographical region and type of clinical samples analyzed, one should 
be aware of potential cross-reactivity against species other than Leishmania. And even 
though our analysis did not identify cross-reactions against 3 other pathogens, such 
problems are region and sample dependent, and a validation should be part of any 
implementation process. In this respect it is also highlighted that these assays are to be 
used in second line for Leishmania species identification, only after performing 
diagnostic – generally more sensitive assays for parasite detection. During 
implementation, it is highly recommended to run all 4 PCRs in parallel to assess the 
performance of each individual PCR by comparing to the combined assay, as was done 
in Table 3.5.1. Once validated, PCR mixes without DNA polymerase can be prepared in 
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bulk and aliquoted, which allows quality control and saves time. When functioning 
properly, there is no need to use all 4 PCRs for analyzing each sample (combined assay 
in Table 3.5.1), and one could suffice by using an appropriate selection depending on 
the exact purpose of the study, and species expected to occur: in endemic settings this 
would typically be the sympatric species, in travel clinics all species can be found. At 
most 100 pg Leishmania DNA should be used in the assays, as cross-reactivity for 
higher concentrations has not been checked for. In clinical samples it is unlikely that a 
higher amount of Leishmania DNA is present, but if uncertain it is advisable to run all 4 
PCRs in parallel to increase the chance of finding unexpected cross-reactions. 
The assays were able to identify the infecting Leishmania species in various clinical 
samples (Fig. 3.5.1), and did not show cross-reaction against Mycobacterium 
tuberculosis, Plasmodium falciparum, or Trypanosoma brucei. 
When L.donovani complex specific PCR assay was tested on 40 confirmed and 20 
suspected VL clinical samples from Sudan, the sensitivity of the suspected was higher 
(100%) than the confirmed cases (97.5) and this can be explained by the presence of the 
high parasitemia in lymph node and bone marrow tissues which were the specimens 
from suspected cases and were blood specimens from confirmed VL cases. 
The high sensitivity of the assay on blood sample is promising towards less invasive 
procedures and even the DNA of the only negative sample was possibly degraded due 
to long storage period although it gave positive result with the SSU PCR assay 
previously. 
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  4.2 CONCLUSION: 
? The entire 22 leishmania isolates lie within the donovani complex in the rDNA-
ITS1 phylogeny with almost identical sequence, and they are all of L.donovani 
sub-species. 
? All four tests (Tryp-PCR-OC, Tryp-NASBA-OC, Leish-PCR-OC and Leish-
NASBA-OC ) demonstrated to be repeatable and reproducible in ring trial study 
and can undergo further phase II and III evaluations in variable laboratory 
settings in disease endemic countries. 
? The Leishmania OligoC-TesT and NASBA-OC showed high sensitivity on 
lymph and blood of VL patients and on scrapings from CL and PKDL patients 
from Sudan. A significant higher specificity for active VL with the NASBA-OC 
than with the OligoC-TesT was observed. Both tests are not yet an option for 
routine diagnosis of leishmaniasis at the primary care level due to their 
infrastructural requirements.  
? The Leishmania OligoC-TesT showed high sensitivity on blood from Kenyan 
patients but a rather low specificity for active disease. In contrast, the sensitivity 
of RNA detection by NASBA-OC on blood from Kenyan patients was lower but 
the specificity was 100%, indicating that it might be a better marker for active 
VL. 
? The rDNA species specific PCR study presents the first step towards a 
standardized Old World Leishmania species typing assay. It focuses on 
validation in cultured samples, with emphasis on implementation of the PCRs in 
other settings, as a starting point for the use in clinical and epidemiological 
studies for which the proof-of-principle was delivered. Validation of the PCRs 
and potential unexpected reactions are essential topics to cover before starting 
any analysis. These assays showed higher sensitivity when tested on clinical 
samples from VL patients from Sudan. 
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4.3 RECOMMENDATION 
? There is a need to obtain more isolates from different parts of the Sudan, 
and characterize them with ITS1 protocol, so as to have   a more 
comprehensive picture of the distribution of the species causing 
leishmaniasis in Sudan. 
? The Leishmania OligoC-TesT and NASBA-OC can be used as powerful 
diagnostic tests in disease surveillance programmes and in monitoring 
intervention studies. 
? The rDNA species specific PCR  can be used on an extended set of 
clinical samples from leishmaniasis patients with different clinical 
presentation as to contribute to the adequate management and follow-up 
of Old World leishmaniasis 
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